kkoh personal page - To The Moon

kkoh

kkoh

No personal profile

3Follow

1Followers

0Topic

0Badge

04-07

Great article, would you like to share it?

Better Growth Biotech Buy: Iovance Biotherapeutics vs CRISPR Therapeutics

2023-11-14

Sea cannot compete with til to on shopping and thus lose money.

Sea Stock Tumbles 22% as the Company Swings Back to Loss After New Rivals Take a Toll

2022-06-10

Us headline inflation is 8 6%. High inflation does not bode well for tech stock. NO wonder focusing and all tech stock drop today

DocuSign Stock Tumbled 24% in Premarket Trading

2022-05-14

Buy only when inflation is peak. Yesterday is bear market rally

7 Tech Stocks Due for a Stunning Short Squeeze

2022-03-30

Quantumscape had a strong moat. So far 4 company had tested using quantumscape battery cell.

QuantumScape Stock Climbed 2% in Premarket Trading

2022-02-25

buy nvidia

Nvidia earning exceed expectation. Buy nvidia on weakness.

2022-02-10

cpi data

If cpi data become worst stock market will sell off. Cpi data expected to increase 0.5% and and will above 17%.

2022-02-06

buy upstart

Buy upstart as PE ratio had drop to attractive level. Upstart is profitable and growth will be strong for the next few quarter.

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3556663321293713","uuid":"3556663321293713","gmtCreate":1593671807187,"gmtModify":1644153362033,"name":"kkoh","pinyin":"kkoh","introduction":"","introductionEn":"","signature":"","avatar":"https://static.itradeup.com/news/043182d0397ab25b04de66a4ae86820d","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":3,"tweetSize":8,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.08.11","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"44212b71d0be4ec88898348dbe882e03-3","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"President Tiger","description":"The transaction amount of the securities account reaches $1,000,000","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"93.45%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.03.17","exceedPercentage":"60.37%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":5,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":292702305870072,"gmtCreate":1712486960172,"gmtModify":1712486963677,"author":{"id":"3556663321293713","authorId":"3556663321293713","name":"kkoh","avatar":"https://static.itradeup.com/news/043182d0397ab25b04de66a4ae86820d","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3556663321293713","authorIdStr":"3556663321293713"},"themes":[],"htmlText":"Great article, would you like to share it?","listText":"Great article, would you like to share it?","text":"Great article, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/292702305870072","repostId":"2425319145","repostType":2,"repost":{"id":"2425319145","kind":"highlight","pubTimestamp":1712307780,"share":"https://ttm.financial/m/news/2425319145?lang=&edition=fundamental","pubTime":"2024-04-05 17:03","market":"fut","language":"en","title":"Better Growth Biotech Buy: Iovance Biotherapeutics vs CRISPR Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2425319145","media":"Motley Fool","summary":"These companies are in the early days of their growth stories.","content":"<html><body><ul>\n<li>\n<div>\n<svg fill=\"none\" height=\"15\" viewbox=\"0 0 14 15\" width=\"14\" xmlns=\"http://www.w3.org/2000/svg\">\n<path d=\"M14 5.58984C14 2.91016 11.8398 0.75 9.16016 0.75C6.50781 0.777344 4.375 2.91016 4.375 5.5625C4.375 6.10938 4.45703 6.60156 4.59375 7.09375L0.191406 11.4961C0.0546875 11.6328 0 11.7969 0 11.9609V14.0938C0 14.4766 0.273438 14.75 0.65625 14.75H3.71875C4.07422 14.75 4.375 14.4766 4.375 14.0938V13H5.46875C5.82422 13 6.125 12.7266 6.125 12.3438V11.25H7.13672C7.30078 11.25 7.51953 11.168 7.62891 11.0312L8.28516 10.293C8.55859 10.3477 8.85938 10.375 9.1875 10.375C11.8398 10.375 14 8.24219 14 5.58984ZM9.1875 4.25C9.1875 3.53906 9.76172 2.9375 10.5 2.9375C11.2109 2.9375 11.8125 3.53906 11.8125 4.25C11.8125 4.98828 11.2109 5.5625 10.5 5.5625C9.76172 5.5625 9.1875 4.98828 9.1875 4.25Z\" fill=\"#FFB81C\"></path>\n</svg>\n</div>\n<div>Both of these companies recently won regulatory approval for their first products.</div>\n</li>\n<li>\n<div>\n<svg fill=\"none\" height=\"15\" viewbox=\"0 0 14 15\" width=\"14\" xmlns=\"http://www.w3.org/2000/svg\">\n<path d=\"M14 5.58984C14 2.91016 11.8398 0.75 9.16016 0.75C6.50781 0.777344 4.375 2.91016 4.375 5.5625C4.375 6.10938 4.45703 6.60156 4.59375 7.09375L0.191406 11.4961C0.0546875 11.6328 0 11.7969 0 11.9609V14.0938C0 14.4766 0.273438 14.75 0.65625 14.75H3.71875C4.07422 14.75 4.375 14.4766 4.375 14.0938V13H5.46875C5.82422 13 6.125 12.7266 6.125 12.3438V11.25H7.13672C7.30078 11.25 7.51953 11.168 7.62891 11.0312L8.28516 10.293C8.55859 10.3477 8.85938 10.375 9.1875 10.375C11.8398 10.375 14 8.24219 14 5.58984ZM9.1875 4.25C9.1875 3.53906 9.76172 2.9375 10.5 2.9375C11.2109 2.9375 11.8125 3.53906 11.8125 4.25C11.8125 4.98828 11.2109 5.5625 10.5 5.5625C9.76172 5.5625 9.1875 4.98828 9.1875 4.25Z\" fill=\"#FFB81C\"></path>\n</svg>\n</div>\n<div>Both Iovance Biotherapeutics and CRISPR <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> have developed game-changing treatment technologies.</div>\n</li>\n</ul><div><p>If you're looking to add some growth to your portfolio, a great way to do it is by picking up shares of a biotech company with a recently approved product. Such a treatment will represent a brand new revenue driver for the company -- and sometimes, even its first one -- so if the product takes off, the share price may follow. In many cases, this marks the very start of the biotech's growth story, allowing you to get in early and benefit over time.</p><p>This is the case for <strong>Iovance Biotherapeutics</strong> <span>(IOVA<span> -2.93%</span>)</span> and <strong>CRISPR Therapeutics</strong> <span>(CRSP<span> 0.71%</span>)</span> today. Each of these biotech players recently won approval for its first product -- and these aren't only regulatory victories, but also votes of confidence in the game-changing technologies they have developed. These stocks both represent interesting growth opportunities today. But if you could only choose one to add to your portfolio, which would be the better buy?</p><div><img loading=\"lazy\" src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F771808%2Fgettyimages-research-team-smiles-in-lab.jpg&amp;op=resize&amp;w=700\" srcset=\"https://g.foolcdn.com/image/?url=https%3A//g.foolcdn.com/editorial/images/771808/gettyimages-research-team-smiles-in-lab.jpg&amp;w=300&amp;op=resize 300w, https://g.foolcdn.com/image/?url=https%3A//g.foolcdn.com/editorial/images/771808/gettyimages-research-team-smiles-in-lab.jpg&amp;w=1000&amp;op=resize 1000w, https://g.foolcdn.com/image/?url=https%3A//g.foolcdn.com/editorial/images/771808/gettyimages-research-team-smiles-in-lab.jpg&amp;w=2000&amp;op=resize 2000w\"/><p>Image source: Getty Images.</p></div><h2>The case for Iovance</h2><p>Iovance recently won accelerated approval for Amtagvi, generically known as lifileucel, a treatment for advanced melanoma -- the most dangerous form of skin cancer. The biotech company has developed an exciting technology that harnesses the power of the patient's own immune system to attack their cancer. To produce Amtagvi, doctors collect tumor-infiltrating lymphocytes (TILs) -- in simple terms, cells that fight cancer -- from the specific patient's tumor. These are then sent to Iovance, which uses them to grow billions more of those same effective cancer-fighting cells, which are then infused back into the patient.</p><div><app :collapse_on_load=\"false\" :instrument_id=\"339444\" :show_benchmark_compare=\"false\" amount_change=\"-0.41\" average_volume=\"9,643,902\" company_name=\"Iovance Biotherapeutics\" current_price=\"13.60\" daily_high=\"14.21\" daily_low=\"13.40\" default_period=\"OneYear\" dividend_yield=\"N/A\" exchange=\"NASDAQ\" fifty_two_week_high=\"18.33\" fifty_two_week_low=\"3.21\" gross_margin=\"-3091.17\" logo=\"https://g.foolcdn.com/art/companylogos/mark/IOVA.png\" market_cap=\"$4B\" pe_ratio=\"-7.18\" percent_change=\"-2.93\" symbol=\"IOVA\" volume=\"3\"></app></div><p>The Amtagvi nod represents the first Food and Drug Administration approval for a one-time, personalized T-cell therapy for a solid tumor cancer. More than 30 authorized treatment centers now are ready to begin delivering it, and Iovance's manufacturing capacity can accommodate several thousand patients annually. The company also has many TIL candidates and TIL combinations with other treatments involved in clinical trials, including a trial in non-small cell lung cancer that may support a regulatory request.</p><p>This year, Iovance should start to collect some revenue from its first TIL product, and this may be just the beginning.</p><div><div></div></div><h2>The case for CRISPR Therapeutics</h2><p>CRISPR Therapeutics specializes in gene-editing therapies based on CRISPR technology. Certain diseases are caused by mutations in a single section of people's genetic code. CRISPR technology uses a natural cellular process to cut a patient's DNA at highly specific locations and insert a new sequence that corrects the faulty mutation that's causing their disease.</p><p>Late last year, CRISPR Therapeutics won the world's first-ever regulatory approval for a product based on CRISPR technology -- Casgevy, a treatment for the blood disorders sickle cell disease and beta-thalassemia.</p><div><app :collapse_on_load=\"false\" :instrument_id=\"338676\" :show_benchmark_compare=\"false\" amount_change=\"0.46\" average_volume=\"1,897,450\" company_name=\"CRISPR Therapeutics\" current_price=\"65.06\" daily_high=\"67.25\" daily_low=\"64.67\" default_period=\"OneYear\" dividend_yield=\"N/A\" exchange=\"NASDAQ\" fifty_two_week_high=\"91.10\" fifty_two_week_low=\"37.55\" gross_margin=\"65.88\" logo=\"https://g.foolcdn.com/art/companylogos/mark/CRSP.png\" market_cap=\"$5B\" pe_ratio=\"-33.01\" percent_change=\"0.71\" symbol=\"CRSP\" volume=\"105\"></app></div><p>The exciting thing about Casgevy and the company's other CRISPR candidates is they represent one-time treatments that (if effective) act as functional cures. This clearly could drive patients to give them a try, especially in diseases with limited treatment options -- like sickle cell disease and beta-thalassemia.</p><p>As for what's ahead, CRISPR Therapeutics has immuno-oncology candidates involved in clinical trials, and aims to launch its first trial in the area of autoimmune diseases in the first half with a candidate to treat systemic lupus erythematosus.</p><div><div></div></div><p>So, like Iovance, CRISPR Therapeutics should start to deliver product revenue this year, and we also should expect clinical trial progress from its pipeline candidates.</p><h2>Iovance or CRISPR Therapeutics?</h2><p>Choosing between Iovance and CRISPR Therapeutics is tough because both of these companies are launching their first products and advancing their pipelines. And each of these stocks has momentum: Iovance has soared by a triple-digit percentage over the past year, and CRISPR Therapeutics is up by close to 50%. But one looks financially stronger, making it the better buy right now.</p><p>CRISPR Therapeutics has a cash position of more than $2.1 billion and has reported some quarters of profitability thanks to collaboration revenue. Iovance has a cash level of about $485 million, up from December thanks to a follow-on round of equity financing. Management expects this and its potential revenue to fund operations through the second half of next year. As for earnings, Iovance's losses have deepened over time.</p><p>This wouldn't drive me away from Iovance, because I do think the company could have a bright future. But if I had to choose between these two stocks right now, I would go for CRISPR Therapeutics because it not only offers solid earnings growth prospects, it also has the financial strength to keep its pipeline momentum going.</p><div></div></div></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Better Growth Biotech Buy: Iovance Biotherapeutics vs CRISPR Therapeutics</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBetter Growth Biotech Buy: Iovance Biotherapeutics vs CRISPR Therapeutics\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-05 17:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2024/04/05/better-growth-biotech-buy-iovance-vs-crispr-therap/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Both of these companies recently won regulatory approval for their first products.\n\n\n\n\n\n\n\nBoth Iovance Biotherapeutics and CRISPR Therapeutics have developed game-changing treatment technologies.\n\nIf ...</p>\n\n<a href=\"https://www.fool.com/investing/2024/04/05/better-growth-biotech-buy-iovance-vs-crispr-therap/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F771808%2Fgettyimages-research-team-smiles-in-lab.jpg&op=resize&w=165&h=104","relate_stocks":{"LU1861558580.USD":"日兴方舟颠覆性创新基金B","LENZ":"Therapeutics","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","CRSP":"CRISPR Therapeutics AG","BK4585":"ETF&股票定投概念","BK4556":"基因编辑","BK4139":"生物科技","BK4588":"碎股"},"source_url":"https://www.fool.com/investing/2024/04/05/better-growth-biotech-buy-iovance-vs-crispr-therap/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2425319145","content_text":"Both of these companies recently won regulatory approval for their first products.\n\n\n\n\n\n\n\nBoth Iovance Biotherapeutics and CRISPR Therapeutics have developed game-changing treatment technologies.\n\nIf you're looking to add some growth to your portfolio, a great way to do it is by picking up shares of a biotech company with a recently approved product. Such a treatment will represent a brand new revenue driver for the company -- and sometimes, even its first one -- so if the product takes off, the share price may follow. In many cases, this marks the very start of the biotech's growth story, allowing you to get in early and benefit over time.This is the case for Iovance Biotherapeutics (IOVA -2.93%) and CRISPR Therapeutics (CRSP 0.71%) today. Each of these biotech players recently won approval for its first product -- and these aren't only regulatory victories, but also votes of confidence in the game-changing technologies they have developed. These stocks both represent interesting growth opportunities today. But if you could only choose one to add to your portfolio, which would be the better buy?Image source: Getty Images.The case for IovanceIovance recently won accelerated approval for Amtagvi, generically known as lifileucel, a treatment for advanced melanoma -- the most dangerous form of skin cancer. The biotech company has developed an exciting technology that harnesses the power of the patient's own immune system to attack their cancer. To produce Amtagvi, doctors collect tumor-infiltrating lymphocytes (TILs) -- in simple terms, cells that fight cancer -- from the specific patient's tumor. These are then sent to Iovance, which uses them to grow billions more of those same effective cancer-fighting cells, which are then infused back into the patient.The Amtagvi nod represents the first Food and Drug Administration approval for a one-time, personalized T-cell therapy for a solid tumor cancer. More than 30 authorized treatment centers now are ready to begin delivering it, and Iovance's manufacturing capacity can accommodate several thousand patients annually. The company also has many TIL candidates and TIL combinations with other treatments involved in clinical trials, including a trial in non-small cell lung cancer that may support a regulatory request.This year, Iovance should start to collect some revenue from its first TIL product, and this may be just the beginning.The case for CRISPR TherapeuticsCRISPR Therapeutics specializes in gene-editing therapies based on CRISPR technology. Certain diseases are caused by mutations in a single section of people's genetic code. CRISPR technology uses a natural cellular process to cut a patient's DNA at highly specific locations and insert a new sequence that corrects the faulty mutation that's causing their disease.Late last year, CRISPR Therapeutics won the world's first-ever regulatory approval for a product based on CRISPR technology -- Casgevy, a treatment for the blood disorders sickle cell disease and beta-thalassemia.The exciting thing about Casgevy and the company's other CRISPR candidates is they represent one-time treatments that (if effective) act as functional cures. This clearly could drive patients to give them a try, especially in diseases with limited treatment options -- like sickle cell disease and beta-thalassemia.As for what's ahead, CRISPR Therapeutics has immuno-oncology candidates involved in clinical trials, and aims to launch its first trial in the area of autoimmune diseases in the first half with a candidate to treat systemic lupus erythematosus.So, like Iovance, CRISPR Therapeutics should start to deliver product revenue this year, and we also should expect clinical trial progress from its pipeline candidates.Iovance or CRISPR Therapeutics?Choosing between Iovance and CRISPR Therapeutics is tough because both of these companies are launching their first products and advancing their pipelines. And each of these stocks has momentum: Iovance has soared by a triple-digit percentage over the past year, and CRISPR Therapeutics is up by close to 50%. But one looks financially stronger, making it the better buy right now.CRISPR Therapeutics has a cash position of more than $2.1 billion and has reported some quarters of profitability thanks to collaboration revenue. Iovance has a cash level of about $485 million, up from December thanks to a follow-on round of equity financing. Management expects this and its potential revenue to fund operations through the second half of next year. As for earnings, Iovance's losses have deepened over time.This wouldn't drive me away from Iovance, because I do think the company could have a bright future. But if I had to choose between these two stocks right now, I would go for CRISPR Therapeutics because it not only offers solid earnings growth prospects, it also has the financial strength to keep its pipeline momentum going.","news_type":1},"isVote":1,"tweetType":1,"viewCount":204,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":241429305721072,"gmtCreate":1699971109107,"gmtModify":1699971112632,"author":{"id":"3556663321293713","authorId":"3556663321293713","name":"kkoh","avatar":"https://static.itradeup.com/news/043182d0397ab25b04de66a4ae86820d","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3556663321293713","authorIdStr":"3556663321293713"},"themes":[],"htmlText":"Sea cannot compete with til to on shopping and thus lose money.","listText":"Sea cannot compete with til to on shopping and thus lose money.","text":"Sea cannot compete with til to on shopping and thus lose money.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/241429305721072","repostId":"1120385949","repostType":2,"repost":{"id":"1120385949","kind":"news","pubTimestamp":1700002879,"share":"https://ttm.financial/m/news/1120385949?lang=&edition=fundamental","pubTime":"2023-11-15 07:01","market":"us","language":"en","title":"Sea Stock Tumbles 22% as the Company Swings Back to Loss After New Rivals Take a Toll","url":"https://stock-news.laohu8.com/highlight/detail?id=1120385949","media":"Bloomberg","summary":"Sea Ltd : Q3 GAAP EPS of -$1.01 misses by $1.01. Revenue of $3.3B  beats by $90M.Sea stock tumbled 14% after posting fiancial results.Total gross profit was US$1.4 billion, up 17.4% year-on-year.Total net loss was US$ million, as compared to total net loss of US$ million for the third quarter of 2022.Total adjusted EBITDA1 was US$35.3 million, as compared to a loss of US$ million for the third quarter of 2022.As of September 30, 2023, cash, cash equivalents, short-term and other treasury investm","content":"<html><head></head><body><p>Sea Ltd. swung back to a loss in the third quarter, hit by flagging consumption and intensifying competition from Alibaba and TikTok on its home turf.</p><p style=\"text-align: start;\">The stock fell 22.07% on Tuesday after the company posted a net loss of $149 million, compared with a profit of $322 million the previous quarter. Southeast Asia’s largest internet firm reported a 4.9% rise in sales from a year earlier to $3.3 billion, versus the average estimate of $3.2 billion.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1a40c2774e9da0111652a2005577043a\" tg-width=\"804\" tg-height=\"624\"/></p><p>The results may stoke concerns that the US-listed company is sacrificing margins to stave off a charge from ByteDance Ltd.’s TikTok and Alibaba Group Holding Ltd.’s Lazada, or newer entrants such as PDD Holdings Inc.’s Temu. Sea plunged its most on record after founder Forrest Li declared in August his company will invest more in online retail arm Shopee and live-streaming to counter those platforms, which are appealing to younger shoppers.</p><p style=\"text-align: start;\">Till recently, Sea’s strongest markets including Indonesia seemed under siege from TikTok and a new breed of video-oriented shopping services, which used popular influencers to sell a range of wares to an engaged, growing online population. But in September, Jakarta effectively forced TikTok to shut its shopping service, acting on a growing backlash from smaller merchants against the Chinese-owned platform.</p><p style=\"text-align: start;\">Investors have been looking for clues since then on whether that abrupt exit will rekindle Sea. Before Indonesia, the market feared the Singaporean company — which reported more than a decade of losses after its 2009 founding — will sink back into the red. Compounding the situation are expectations that Southeast Asia’s internet economy will log its slowest growth on record this year, the result of an economic downturn with uncertain outcomes.</p><p style=\"text-align: start;\">Sea’s other big business, the gaming division centered around Garena, has shrunk rapidly in 2023 given a lack of new blockbuster titles. But it recently restored its marquee title Free Fire to Indian app stores after a surprise 2022 ban.</p><blockquote><p>Sea’s e-commerce revenue, driving 68% of the 1H total, should gain from Indonesian regulators’ shutdown of TikTok’s shopping platform, which faces similar risks in Malaysia. Online-shopping gross merchandise value (GMV) likely fell or stagnated in 1Q-2Q, a trend that could improve as Shopee regains lost market share from rivals amid a reacceleration in marketing spending. With Temu, the overseas arm of China’s e-tailer Pinduoduo also encroaching on Southeast Asia, such investments could intensify and cloud Sea’s net profit path. This is partially mitigated by a tepid recovery in the digital entertainment segment — driving 45% of 1H adjusted Ebitda — amid a rebound in Free Fire’s player engagement.</p><p>Free cash flow could remain under pressure amid e-commerce expansion spending. - Nathan Naidu, analyst</p></blockquote><p style=\"text-align: start;\">Li’s company had overhauled its business to focus on profitability earlier this year. Sea embarked on an aggressive cost-cutting drive to reach profit, pivoting to a focus on the bottom-line as revenue growth decelerated from the triple-digit percentage rates it enjoyed as recently as two years ago. The company froze salaries and slashed hundreds of millions of dollars in expenses to achieve positive cash flows.</p><p style=\"text-align: start;\">To jumpstart growth, Li said in August he intends to ramp up investments into e-commerce arm Shopee. He is stepping up efforts to build out its live-streaming arm, an offensive move that could erode margins and trigger a price war with TikTok and Alibaba. He argued that was necessary to defend its market share.</p><p style=\"text-align: start;\">Beyond deep-pocketed competitors Alibaba and ByteDance, local rivals such as GoTo Group are also piling the pressure on Sea. GoTo, owner of Indonesian e-commerce contender Tokopedia, almost doubled its net revenue during the June quarter.</p></body></html>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sea Stock Tumbles 22% as the Company Swings Back to Loss After New Rivals Take a Toll</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSea Stock Tumbles 22% as the Company Swings Back to Loss After New Rivals Take a Toll\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-11-15 07:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2023-11-14/singapore-s-sea-swings-back-to-loss-after-new-rivals-take-a-toll><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sea Ltd. swung back to a loss in the third quarter, hit by flagging consumption and intensifying competition from Alibaba and TikTok on its home turf.The stock fell 22.07% on Tuesday after the company...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2023-11-14/singapore-s-sea-swings-back-to-loss-after-new-rivals-take-a-toll\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SE":"Sea Ltd"},"source_url":"https://www.bloomberg.com/news/articles/2023-11-14/singapore-s-sea-swings-back-to-loss-after-new-rivals-take-a-toll","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1120385949","content_text":"Sea Ltd. swung back to a loss in the third quarter, hit by flagging consumption and intensifying competition from Alibaba and TikTok on its home turf.The stock fell 22.07% on Tuesday after the company posted a net loss of $149 million, compared with a profit of $322 million the previous quarter. Southeast Asia’s largest internet firm reported a 4.9% rise in sales from a year earlier to $3.3 billion, versus the average estimate of $3.2 billion.The results may stoke concerns that the US-listed company is sacrificing margins to stave off a charge from ByteDance Ltd.’s TikTok and Alibaba Group Holding Ltd.’s Lazada, or newer entrants such as PDD Holdings Inc.’s Temu. Sea plunged its most on record after founder Forrest Li declared in August his company will invest more in online retail arm Shopee and live-streaming to counter those platforms, which are appealing to younger shoppers.Till recently, Sea’s strongest markets including Indonesia seemed under siege from TikTok and a new breed of video-oriented shopping services, which used popular influencers to sell a range of wares to an engaged, growing online population. But in September, Jakarta effectively forced TikTok to shut its shopping service, acting on a growing backlash from smaller merchants against the Chinese-owned platform.Investors have been looking for clues since then on whether that abrupt exit will rekindle Sea. Before Indonesia, the market feared the Singaporean company — which reported more than a decade of losses after its 2009 founding — will sink back into the red. Compounding the situation are expectations that Southeast Asia’s internet economy will log its slowest growth on record this year, the result of an economic downturn with uncertain outcomes.Sea’s other big business, the gaming division centered around Garena, has shrunk rapidly in 2023 given a lack of new blockbuster titles. But it recently restored its marquee title Free Fire to Indian app stores after a surprise 2022 ban.Sea’s e-commerce revenue, driving 68% of the 1H total, should gain from Indonesian regulators’ shutdown of TikTok’s shopping platform, which faces similar risks in Malaysia. Online-shopping gross merchandise value (GMV) likely fell or stagnated in 1Q-2Q, a trend that could improve as Shopee regains lost market share from rivals amid a reacceleration in marketing spending. With Temu, the overseas arm of China’s e-tailer Pinduoduo also encroaching on Southeast Asia, such investments could intensify and cloud Sea’s net profit path. This is partially mitigated by a tepid recovery in the digital entertainment segment — driving 45% of 1H adjusted Ebitda — amid a rebound in Free Fire’s player engagement.Free cash flow could remain under pressure amid e-commerce expansion spending. - Nathan Naidu, analystLi’s company had overhauled its business to focus on profitability earlier this year. Sea embarked on an aggressive cost-cutting drive to reach profit, pivoting to a focus on the bottom-line as revenue growth decelerated from the triple-digit percentage rates it enjoyed as recently as two years ago. The company froze salaries and slashed hundreds of millions of dollars in expenses to achieve positive cash flows.To jumpstart growth, Li said in August he intends to ramp up investments into e-commerce arm Shopee. He is stepping up efforts to build out its live-streaming arm, an offensive move that could erode margins and trigger a price war with TikTok and Alibaba. He argued that was necessary to defend its market share.Beyond deep-pocketed competitors Alibaba and ByteDance, local rivals such as GoTo Group are also piling the pressure on Sea. GoTo, owner of Indonesian e-commerce contender Tokopedia, almost doubled its net revenue during the June quarter.","news_type":1},"isVote":1,"tweetType":1,"viewCount":195,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9058550456,"gmtCreate":1654868221175,"gmtModify":1676535525318,"author":{"id":"3556663321293713","authorId":"3556663321293713","name":"kkoh","avatar":"https://static.itradeup.com/news/043182d0397ab25b04de66a4ae86820d","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3556663321293713","authorIdStr":"3556663321293713"},"themes":[],"htmlText":"Us&nbsp; headline inflation is 8 6%. High inflation does not bode well for tech stock. NO wonder focusing and all tech stock drop today","listText":"Us&nbsp; headline inflation is 8 6%. High inflation does not bode well for tech stock. NO wonder focusing and all tech stock drop today","text":"Us headline inflation is 8 6%. High inflation does not bode well for tech stock. NO wonder focusing and all tech stock drop today","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9058550456","repostId":"1179770116","repostType":4,"repost":{"id":"1179770116","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1654849697,"share":"https://ttm.financial/m/news/1179770116?lang=&edition=fundamental","pubTime":"2022-06-10 16:28","market":"us","language":"en","title":"DocuSign Stock Tumbled 24% in Premarket Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1179770116","media":"Tiger Newspress","summary":"DocuSign reported earnings that missed expectations for the April quarter, sending the stock lower i","content":"<html><head></head><body><p><a href=\"https://laohu8.com/S/DOCU\">DocuSign</a> reported earnings that missed expectations for the April quarter, sending the stock lower in premarket trading.</p><p>The electronic signature documents company reported fiscal first-quarter adjusted earnings per share of 38 cents, compared with Wall Street&#39;s consensus estimate of 46 cents, according to FactSet. Revenue came in at $589 million, which was slightly above analysts&#39; expectations of $583 million. DocuSign also gave a guidance range of between $600 million to $604 million for the current quarter versus the $601 million consensus.<img src=\"https://static.tigerbbs.com/832ac4cdc3514845d41e0f475e2563c8\" tg-width=\"843\" tg-height=\"675\" width=\"100%\" height=\"auto\"/>&#34;With over a billion users worldwide, the proven value of our products, and the significant opportunity we have ahead of us, we&#39;re confident in our ability to successfully navigate the challenges of a dynamic global environment,&#34; Dan Springer, CEO of DocuSign, said in a statement.</p><p>Earlier this year, DocuSign had provided an outlook that disappointed Wall Street.</p><p>Wall Street analysts have been mixed on DocuSign. About 50% have ratings of Buy or the equivalent on the stock, while roughly 45% have Hold ratings on the shares, according to FactSet.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>DocuSign Stock Tumbled 24% in Premarket Trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDocuSign Stock Tumbled 24% in Premarket Trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-06-10 16:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p><a href=\"https://laohu8.com/S/DOCU\">DocuSign</a> reported earnings that missed expectations for the April quarter, sending the stock lower in premarket trading.</p><p>The electronic signature documents company reported fiscal first-quarter adjusted earnings per share of 38 cents, compared with Wall Street&#39;s consensus estimate of 46 cents, according to FactSet. Revenue came in at $589 million, which was slightly above analysts&#39; expectations of $583 million. DocuSign also gave a guidance range of between $600 million to $604 million for the current quarter versus the $601 million consensus.<img src=\"https://static.tigerbbs.com/832ac4cdc3514845d41e0f475e2563c8\" tg-width=\"843\" tg-height=\"675\" width=\"100%\" height=\"auto\"/>&#34;With over a billion users worldwide, the proven value of our products, and the significant opportunity we have ahead of us, we&#39;re confident in our ability to successfully navigate the challenges of a dynamic global environment,&#34; Dan Springer, CEO of DocuSign, said in a statement.</p><p>Earlier this year, DocuSign had provided an outlook that disappointed Wall Street.</p><p>Wall Street analysts have been mixed on DocuSign. About 50% have ratings of Buy or the equivalent on the stock, while roughly 45% have Hold ratings on the shares, according to FactSet.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DOCU":"Docusign"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1179770116","content_text":"DocuSign reported earnings that missed expectations for the April quarter, sending the stock lower in premarket trading.The electronic signature documents company reported fiscal first-quarter adjusted earnings per share of 38 cents, compared with Wall Street's consensus estimate of 46 cents, according to FactSet. Revenue came in at $589 million, which was slightly above analysts' expectations of $583 million. DocuSign also gave a guidance range of between $600 million to $604 million for the current quarter versus the $601 million consensus.\"With over a billion users worldwide, the proven value of our products, and the significant opportunity we have ahead of us, we're confident in our ability to successfully navigate the challenges of a dynamic global environment,\" Dan Springer, CEO of DocuSign, said in a statement.Earlier this year, DocuSign had provided an outlook that disappointed Wall Street.Wall Street analysts have been mixed on DocuSign. About 50% have ratings of Buy or the equivalent on the stock, while roughly 45% have Hold ratings on the shares, according to FactSet.","news_type":1},"isVote":1,"tweetType":1,"viewCount":288,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9067474560,"gmtCreate":1652503084250,"gmtModify":1676535113718,"author":{"id":"3556663321293713","authorId":"3556663321293713","name":"kkoh","avatar":"https://static.itradeup.com/news/043182d0397ab25b04de66a4ae86820d","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3556663321293713","authorIdStr":"3556663321293713"},"themes":[],"htmlText":"Buy only when inflation is peak. Yesterday is bear market rally","listText":"Buy only when inflation is peak. Yesterday is bear market rally","text":"Buy only when inflation is peak. Yesterday is bear market rally","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9067474560","repostId":"1142625526","repostType":2,"repost":{"id":"1142625526","kind":"news","pubTimestamp":1652488791,"share":"https://ttm.financial/m/news/1142625526?lang=&edition=fundamental","pubTime":"2022-05-14 08:39","market":"us","language":"en","title":"7 Tech Stocks Due for a Stunning Short Squeeze","url":"https://stock-news.laohu8.com/highlight/detail?id=1142625526","media":"investorplace","summary":"Each of these tech stocks to buy are approaching critical bounce levels.Advanced Micro Devices (AMD)","content":"<html><head></head><body><ul><li>Each of these tech stocks to buy are approaching critical bounce levels.</li><li>Advanced Micro Devices (AMD) stock is hot and cheap.</li><li>Nvidia (NVDA) is the new trend-setter.</li><li>Intel (INTC) is s dirt cheap tech behemoth.</li><li>Microsoft (MSFT) represents the most improved old dog on the Street.</li><li>Tesla (TSLA) continues to lead the electric vehicle space.</li><li>Shopify (SHOP) is reinventing the world Amazon created.</li><li>Amazon (AMZN) is a titan that continues to make great moves.</li></ul><p>Wall Street is a total mess this week, but the list of tech stocks to buy remains quite large. Equities and other asset classes are in free fall. Even Bitcoin (BTC-USD) is now below $30,000. The tech stocks I’ve identified today are all likely to experience sharp recoveries soon enough.</p><p>We should recognize that there are short-term risks, like yesterday the indices fell 2.5%. More proof of the chaos is that the CBOE volatility index (INDEXCBOE:VIX) also closed red. Since bond yields also fell, we should not blame the inflation report. Regardless, most companies are still reporting strong P&amp;L’s. Even Upstart (NASDAQ:UPST) collapsed despite growing sales 150%. Risk appetite is very particular these days, and investors favor less frothy tickers.</p><p>I limited my list of tech stocks to include nothing but outstanding companies. The uneasiness in the stock market will abate after a while, as the hawkish Federal Reserve rhetoric becomes stale. Meanwhile, the indices have room to fall another 12% to 20% from here. Therefore, tech stocks may not have hit an absolute bottom. So it would be a wise to throttle deployment of new trades.</p><p>Long term, the overwhelming bullish thesis is that the world is absolutely going digital.  This is a one-way trend and we will need smart machines to make that happen. Overall, demand for these products and services will linger for a decade.</p><p><img src=\"https://static.tigerbbs.com/ab339ae06fbe3e2c4f403220172a7381\" tg-width=\"1117\" tg-height=\"447\" width=\"100%\" height=\"auto\"/></p><h2>Advanced Micro Devices (AMD)</h2><p>I will start with a successful company that provides brains to the operations. The world needs computers and Advanced Micro Devices (NASDAQ:AMD) provides strong processing power to make that happen. The company’s fundamentals are excellent, and it’s relatively cheap. Its reputation has grown to the point that it has staunch fans. I, for one, have recently purchased two computers with AMD internals.</p><p>The stock chart is approaching a support zone above $75 per share. There are likely to be bulls lurking there waiting to buy it. This has served as a base since summer of 2020. However, investors should look out for small technical hiccups to close a few gaps below that. Below these levels, AMD would make for an excellent value proposition. The rally back should be violent, because Wall Street habitually overdoes things. The bears cannot help but overstay their welcome into winning trades.</p><h2>Nvidia (NVDA)</h2><p>Nvidia (NASDAQ:NVDA) stock is suffering a similar fate to AMD. It is its chief headline rival also providing excellent brains to our highly technical world. Nvidia has earned the reputation of the lead innovator in the field. Their financial results support these claims with absolute certainty. Nvidia management grew its revenues more than five times since 2015. They even boast a $10 billion net income. Last year they generated $9 billion in cash from their operations.</p><p>However, the stock is not cheap, especially relative to its competition. With a price-to-sales ratio of 17x, it could lose a bit of froth to bring that more in line. Nevertheless, the stock is also falling into a sharp pivotal zone. The support extends from current price through $138 per share. Those levels have been in contention also since 2020, so they will provide support.</p><p>This stock is also in a bearish pattern that may have a few more bucks to go. All it needs is for the indices to stabilize and it will too. There’s no doubt of Nvidia’s excellence, and the buyers will come back to it with force. The rally back should be more violent than the sellers may yet realize.</p><h2>Intel (INTC)</h2><p>While Nvidia and AMD hog the headlines, Intel is still the behemoth they are both chasing. Most investors don’t realize that Intel (NASDAQ:INTC) is larger than the other two twice over. It is still a beast, but not as exciting. Eventually they recapture the investor imagination and earn back the respect they lost. Fundamentally this is the cheapest of them all by a mile.</p><p>From a charts perspective, INTC stock has had strong support around $40 per share since 2018. Investors who hold the stock have strong hands. They are not likely to capitulate easily. There is technical risk just like the other two, but it’s likely to find support soon. The rally back in this one may not be as ferocious as the other two. This makes it carry a bit less risk over all.</p><h2>Microsoft (MSFT)</h2><p>Microsoft (NASDAQ:MSFT) is an old dog that lived through the dot com bubble. MSFT stock has lost 25% of its value since the high it set last fall. Since it lost the support from early March, it could even overshoot a bit lower from here. But if the indices stabilize, Microsoft has technical reasons to rally back 15% and quickly.</p><p>This company proved itself worthy of trust. Microsoft was able to shift a giant ship and steer it straight into winning trends. Under the leadership of Satya Nadella, the company made it look easy too. Wall Street rewarded MSFT for its efforts, as the stock still is miles away from its pandemic lows. While it is not cheap, there isn’t obvious bloat either. Revenues for the trailing 12 months doubled from five years ago. With a net income of $70 billion, investors can sit through a few bumps along the way. If I were long the stock I can confidently wait out these jitters.</p><h2>Tesla (TSLA)</h2><p>While you might not see electric vehicle maker Tesla (NASDAQ:TSLA) as a tech stock, it’s full of technology, so I’m keeping it on this list. Currently its financials are impeccable and twice as efficient with its gross margin compared to Ford (NYSE:F) or General Motors (NYSE:GM).</p><p>Tesla stock is a bigger beast than the company itself. Over time it has slayed many shorts. Not yesterday though, as it fell 8% and for no specific reason. However it is still doing relatively better than the indices. At least it has not yet lost its support from Feb. 24. But therein lies some technical risk. If TSLA falls below $697 per share, it could accelerate lower.</p><p>I am confident that once it stabilizes Tesla will slay more bears. The rally back will be ferocious, so investors should avoid shorting it. Smart money would look for entries near support spots below. It too will need help from the overall markets.</p><h2>Shopify (SHOP)</h2><p>The line between tech and retail companies is paper thin. Therefore, I’m including Shopify (NYSE:SHOP) in my list of tech stocks to buy. If there is a stock that can rally fast, SHOP stock is it. Unfortunately it does so in both directions. Case in point, the company just lost 80% of its value since last November. Luckily it had just rallied over 200% out of the pandemic.</p><p>SHOP stock took a long round trip road to $1,760 and closed under $320 on Wednesday. Investors drove it straight into the pandemic base. Once it comes back into style, the buyers will overdo it one more time. It is hard to quantify the size of the rebound, as it is hard to pinpoint the absolute bottom. Therefore, taking small bites is best.</p><p>Management grew revenues seven-fold in five years. And they did that without creating excessive valuation. Its humble price-to-sales suggests that owners now have realistic expectations. Moderation is an extremely important virtue when dealing with Shopify stock.</p><h2>Amazon (AMZN)</h2><p>If we include SHOP, then Amazon (NASDAQ:AMZN) also belongs on this list. After all, Amazon essentially owns the cloud, so most tech-related things pass through their servers.</p><p>It too has had a bad time on Wall Street of late. Amazon stock is 44% below its all-time highs. It is also approaching a very sharp consolidation zone. Unfortunately it is also wide, so the floor is more of a band of support. Going all-in to catch this falling machete would be reckless.</p><p>Its fundamentals are beyond reproach and its financial metrics are strong. Amazon generates $470 billion in revenues and $20 billion in net income. It has 1the means to do whatever it wants to grow the business further. The team is rarely short on imagination and it has earned every benefit of the doubt. This is a tech stock I could own for a lifetime.</p></body></html>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>7 Tech Stocks Due for a Stunning Short Squeeze</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n7 Tech Stocks Due for a Stunning Short Squeeze\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-14 08:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/05/7-tech-stocks-due-for-a-stunning-short-squeeze/><strong>investorplace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Each of these tech stocks to buy are approaching critical bounce levels.Advanced Micro Devices (AMD) stock is hot and cheap.Nvidia (NVDA) is the new trend-setter.Intel (INTC) is s dirt cheap tech ...</p>\n\n<a href=\"https://investorplace.com/2022/05/7-tech-stocks-due-for-a-stunning-short-squeeze/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MSFT":"微软","AMD":"美国超微公司","NVDA":"英伟达","SHOP":"Shopify Inc","TSLA":"特斯拉","AMZN":"亚马逊","INTC":"英特尔"},"source_url":"https://investorplace.com/2022/05/7-tech-stocks-due-for-a-stunning-short-squeeze/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1142625526","content_text":"Each of these tech stocks to buy are approaching critical bounce levels.Advanced Micro Devices (AMD) stock is hot and cheap.Nvidia (NVDA) is the new trend-setter.Intel (INTC) is s dirt cheap tech behemoth.Microsoft (MSFT) represents the most improved old dog on the Street.Tesla (TSLA) continues to lead the electric vehicle space.Shopify (SHOP) is reinventing the world Amazon created.Amazon (AMZN) is a titan that continues to make great moves.Wall Street is a total mess this week, but the list of tech stocks to buy remains quite large. Equities and other asset classes are in free fall. Even Bitcoin (BTC-USD) is now below $30,000. The tech stocks I’ve identified today are all likely to experience sharp recoveries soon enough.We should recognize that there are short-term risks, like yesterday the indices fell 2.5%. More proof of the chaos is that the CBOE volatility index (INDEXCBOE:VIX) also closed red. Since bond yields also fell, we should not blame the inflation report. Regardless, most companies are still reporting strong P&L’s. Even Upstart (NASDAQ:UPST) collapsed despite growing sales 150%. Risk appetite is very particular these days, and investors favor less frothy tickers.I limited my list of tech stocks to include nothing but outstanding companies. The uneasiness in the stock market will abate after a while, as the hawkish Federal Reserve rhetoric becomes stale. Meanwhile, the indices have room to fall another 12% to 20% from here. Therefore, tech stocks may not have hit an absolute bottom. So it would be a wise to throttle deployment of new trades.Long term, the overwhelming bullish thesis is that the world is absolutely going digital.  This is a one-way trend and we will need smart machines to make that happen. Overall, demand for these products and services will linger for a decade.Advanced Micro Devices (AMD)I will start with a successful company that provides brains to the operations. The world needs computers and Advanced Micro Devices (NASDAQ:AMD) provides strong processing power to make that happen. The company’s fundamentals are excellent, and it’s relatively cheap. Its reputation has grown to the point that it has staunch fans. I, for one, have recently purchased two computers with AMD internals.The stock chart is approaching a support zone above $75 per share. There are likely to be bulls lurking there waiting to buy it. This has served as a base since summer of 2020. However, investors should look out for small technical hiccups to close a few gaps below that. Below these levels, AMD would make for an excellent value proposition. The rally back should be violent, because Wall Street habitually overdoes things. The bears cannot help but overstay their welcome into winning trades.Nvidia (NVDA)Nvidia (NASDAQ:NVDA) stock is suffering a similar fate to AMD. It is its chief headline rival also providing excellent brains to our highly technical world. Nvidia has earned the reputation of the lead innovator in the field. Their financial results support these claims with absolute certainty. Nvidia management grew its revenues more than five times since 2015. They even boast a $10 billion net income. Last year they generated $9 billion in cash from their operations.However, the stock is not cheap, especially relative to its competition. With a price-to-sales ratio of 17x, it could lose a bit of froth to bring that more in line. Nevertheless, the stock is also falling into a sharp pivotal zone. The support extends from current price through $138 per share. Those levels have been in contention also since 2020, so they will provide support.This stock is also in a bearish pattern that may have a few more bucks to go. All it needs is for the indices to stabilize and it will too. There’s no doubt of Nvidia’s excellence, and the buyers will come back to it with force. The rally back should be more violent than the sellers may yet realize.Intel (INTC)While Nvidia and AMD hog the headlines, Intel is still the behemoth they are both chasing. Most investors don’t realize that Intel (NASDAQ:INTC) is larger than the other two twice over. It is still a beast, but not as exciting. Eventually they recapture the investor imagination and earn back the respect they lost. Fundamentally this is the cheapest of them all by a mile.From a charts perspective, INTC stock has had strong support around $40 per share since 2018. Investors who hold the stock have strong hands. They are not likely to capitulate easily. There is technical risk just like the other two, but it’s likely to find support soon. The rally back in this one may not be as ferocious as the other two. This makes it carry a bit less risk over all.Microsoft (MSFT)Microsoft (NASDAQ:MSFT) is an old dog that lived through the dot com bubble. MSFT stock has lost 25% of its value since the high it set last fall. Since it lost the support from early March, it could even overshoot a bit lower from here. But if the indices stabilize, Microsoft has technical reasons to rally back 15% and quickly.This company proved itself worthy of trust. Microsoft was able to shift a giant ship and steer it straight into winning trends. Under the leadership of Satya Nadella, the company made it look easy too. Wall Street rewarded MSFT for its efforts, as the stock still is miles away from its pandemic lows. While it is not cheap, there isn’t obvious bloat either. Revenues for the trailing 12 months doubled from five years ago. With a net income of $70 billion, investors can sit through a few bumps along the way. If I were long the stock I can confidently wait out these jitters.Tesla (TSLA)While you might not see electric vehicle maker Tesla (NASDAQ:TSLA) as a tech stock, it’s full of technology, so I’m keeping it on this list. Currently its financials are impeccable and twice as efficient with its gross margin compared to Ford (NYSE:F) or General Motors (NYSE:GM).Tesla stock is a bigger beast than the company itself. Over time it has slayed many shorts. Not yesterday though, as it fell 8% and for no specific reason. However it is still doing relatively better than the indices. At least it has not yet lost its support from Feb. 24. But therein lies some technical risk. If TSLA falls below $697 per share, it could accelerate lower.I am confident that once it stabilizes Tesla will slay more bears. The rally back will be ferocious, so investors should avoid shorting it. Smart money would look for entries near support spots below. It too will need help from the overall markets.Shopify (SHOP)The line between tech and retail companies is paper thin. Therefore, I’m including Shopify (NYSE:SHOP) in my list of tech stocks to buy. If there is a stock that can rally fast, SHOP stock is it. Unfortunately it does so in both directions. Case in point, the company just lost 80% of its value since last November. Luckily it had just rallied over 200% out of the pandemic.SHOP stock took a long round trip road to $1,760 and closed under $320 on Wednesday. Investors drove it straight into the pandemic base. Once it comes back into style, the buyers will overdo it one more time. It is hard to quantify the size of the rebound, as it is hard to pinpoint the absolute bottom. Therefore, taking small bites is best.Management grew revenues seven-fold in five years. And they did that without creating excessive valuation. Its humble price-to-sales suggests that owners now have realistic expectations. Moderation is an extremely important virtue when dealing with Shopify stock.Amazon (AMZN)If we include SHOP, then Amazon (NASDAQ:AMZN) also belongs on this list. After all, Amazon essentially owns the cloud, so most tech-related things pass through their servers.It too has had a bad time on Wall Street of late. Amazon stock is 44% below its all-time highs. It is also approaching a very sharp consolidation zone. Unfortunately it is also wide, so the floor is more of a band of support. Going all-in to catch this falling machete would be reckless.Its fundamentals are beyond reproach and its financial metrics are strong. Amazon generates $470 billion in revenues and $20 billion in net income. It has 1the means to do whatever it wants to grow the business further. The team is rarely short on imagination and it has earned every benefit of the doubt. This is a tech stock I could own for a lifetime.","news_type":1},"isVote":1,"tweetType":1,"viewCount":106,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9019406573,"gmtCreate":1648616899754,"gmtModify":1676534365973,"author":{"id":"3556663321293713","authorId":"3556663321293713","name":"kkoh","avatar":"https://static.itradeup.com/news/043182d0397ab25b04de66a4ae86820d","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3556663321293713","authorIdStr":"3556663321293713"},"themes":[],"htmlText":"Quantumscape had a strong moat. So far 4 company had tested using quantumscape battery cell.","listText":"Quantumscape had a strong moat. So far 4 company had tested using quantumscape battery cell.","text":"Quantumscape had a strong moat. So far 4 company had tested using quantumscape battery cell.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9019406573","repostId":"1149825957","repostType":2,"repost":{"id":"1149825957","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1648541504,"share":"https://ttm.financial/m/news/1149825957?lang=&edition=fundamental","pubTime":"2022-03-29 16:11","market":"us","language":"en","title":"QuantumScape Stock Climbed 2% in Premarket Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1149825957","media":"Tiger Newspress","summary":"QuantumScape stock climbed 2% in premarket trading as QuantumScape's relation with Volkswagen could ","content":"<html><head></head><body><p>QuantumScape stock climbed 2% in premarket trading as QuantumScape&#39;s relation with Volkswagen could deepen further.</p><p><img src=\"https://static.tigerbbs.com/b02c0c6314ab8182d99cbe693baaaa26\" tg-width=\"841\" tg-height=\"620\" width=\"100%\" height=\"auto\"/></p><p>According to the <i>Manager Magazin</i> article<i>,</i><b>Volkswagen</b>&#39;s luxury brand Porsche, best known for its 911 sports car, is reportedly developing an electric version of the 911 that could use solid-state batteries, and is working with QuantumScape to supply them.</p><p>Although neither QuantumScape nor Porsche have confirmed anything yet, investors were perhaps betting on this rumor proving  true, given the company&#39;s long-standing partnership with Volkswagen.</p><p>In 2021, QuantumScape received an additional $100 million worth of funding from Volkswagen after its battery cells met the automaker&#39;s technical milestone requirements in lab tests. The two companies have also signed an agreement to jointly develop a solid-state battery pilot-line facility.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>QuantumScape Stock Climbed 2% in Premarket Trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nQuantumScape Stock Climbed 2% in Premarket Trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-03-29 16:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>QuantumScape stock climbed 2% in premarket trading as QuantumScape&#39;s relation with Volkswagen could deepen further.</p><p><img src=\"https://static.tigerbbs.com/b02c0c6314ab8182d99cbe693baaaa26\" tg-width=\"841\" tg-height=\"620\" width=\"100%\" height=\"auto\"/></p><p>According to the <i>Manager Magazin</i> article<i>,</i><b>Volkswagen</b>&#39;s luxury brand Porsche, best known for its 911 sports car, is reportedly developing an electric version of the 911 that could use solid-state batteries, and is working with QuantumScape to supply them.</p><p>Although neither QuantumScape nor Porsche have confirmed anything yet, investors were perhaps betting on this rumor proving  true, given the company&#39;s long-standing partnership with Volkswagen.</p><p>In 2021, QuantumScape received an additional $100 million worth of funding from Volkswagen after its battery cells met the automaker&#39;s technical milestone requirements in lab tests. The two companies have also signed an agreement to jointly develop a solid-state battery pilot-line facility.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"QS":"Quantumscape Corp."},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1149825957","content_text":"QuantumScape stock climbed 2% in premarket trading as QuantumScape's relation with Volkswagen could deepen further.According to the Manager Magazin article,Volkswagen's luxury brand Porsche, best known for its 911 sports car, is reportedly developing an electric version of the 911 that could use solid-state batteries, and is working with QuantumScape to supply them.Although neither QuantumScape nor Porsche have confirmed anything yet, investors were perhaps betting on this rumor proving  true, given the company's long-standing partnership with Volkswagen.In 2021, QuantumScape received an additional $100 million worth of funding from Volkswagen after its battery cells met the automaker's technical milestone requirements in lab tests. The two companies have also signed an agreement to jointly develop a solid-state battery pilot-line facility.","news_type":1},"isVote":1,"tweetType":1,"viewCount":241,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9030569249,"gmtCreate":1645756364592,"gmtModify":1676534061456,"author":{"id":"3556663321293713","authorId":"3556663321293713","name":"kkoh","avatar":"https://static.itradeup.com/news/043182d0397ab25b04de66a4ae86820d","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3556663321293713","authorIdStr":"3556663321293713"},"themes":[],"title":"buy nvidia","htmlText":"Nvidia earning exceed expectation. Buy nvidia on weakness.","listText":"Nvidia earning exceed expectation. Buy nvidia on weakness.","text":"Nvidia earning exceed expectation. Buy nvidia on weakness.","images":[],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9030569249","isVote":1,"tweetType":1,"viewCount":108,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9096771977,"gmtCreate":1644473142430,"gmtModify":1676533931327,"author":{"id":"3556663321293713","authorId":"3556663321293713","name":"kkoh","avatar":"https://static.itradeup.com/news/043182d0397ab25b04de66a4ae86820d","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3556663321293713","authorIdStr":"3556663321293713"},"themes":[],"title":"cpi data","htmlText":"If cpi data become worst stock market will sell off. Cpi data expected to increase 0.5% and and will above 17%.","listText":"If cpi data become worst stock market will sell off. Cpi data expected to increase 0.5% and and will above 17%.","text":"If cpi data become worst stock market will sell off. Cpi data expected to increase 0.5% and and will above 17%.","images":[],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9096771977","isVote":1,"tweetType":1,"viewCount":416,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9098229177,"gmtCreate":1644151048749,"gmtModify":1676533894523,"author":{"id":"3556663321293713","authorId":"3556663321293713","name":"kkoh","avatar":"https://static.itradeup.com/news/043182d0397ab25b04de66a4ae86820d","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3556663321293713","authorIdStr":"3556663321293713"},"themes":[],"title":"buy upstart","htmlText":"Buy upstart as PE ratio had drop to attractive level. Upstart is profitable and growth will be strong for the next few quarter.","listText":"Buy upstart as PE ratio had drop to attractive level. Upstart is profitable and growth will be strong for the next few quarter.","text":"Buy upstart as PE ratio had drop to attractive level. Upstart is profitable and growth will be strong for the next few quarter.","images":[],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9098229177","isVote":1,"tweetType":1,"viewCount":554,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3479274777284002","authorId":"3479274777284002","name":"zoomzi","avatar":"https://static.tigerbbs.com/79994bc77de771ec5e7fabc95b9d921d","crmLevel":1,"crmLevelSwitch":0,"idStr":"3479274777284002","authorIdStr":"3479274777284002"},"content":"The company is an intelligent lending platform based on cloud and AI. The platform of the company brings together consumers' demand for high-quality loans and connects it with its emerging AI banking partner network. Consumers on this platform can benefit from higher approval rates, lower interest rates and a highly automated and efficient all-digital experience. Its bank partners benefit from contacting new customers, reducing fraud and loss rates, and improving the automation of the whole loan process. To sum up, upstart is a very good company.","text":"The company is an intelligent lending platform based on cloud and AI. The platform of the company brings together consumers' demand for high-quality loans and connects it with its emerging AI banking partner network. Consumers on this platform can benefit from higher approval rates, lower interest rates and a highly automated and efficient all-digital experience. Its bank partners benefit from contacting new customers, reducing fraud and loss rates, and improving the automation of the whole loan process. To sum up, upstart is a very good company.","html":"The company is an intelligent lending platform based on cloud and AI. The platform of the company brings together consumers' demand for high-quality loans and connects it with its emerging AI banking partner network. Consumers on this platform can benefit from higher approval rates, lower interest rates and a highly automated and efficient all-digital experience. Its bank partners benefit from contacting new customers, reducing fraud and loss rates, and improving the automation of the whole loan process. To sum up, upstart is a very good company."}],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":9098229177,"gmtCreate":1644151048749,"gmtModify":1676533894523,"author":{"id":"3556663321293713","authorId":"3556663321293713","name":"kkoh","avatar":"https://static.itradeup.com/news/043182d0397ab25b04de66a4ae86820d","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3556663321293713","authorIdStr":"3556663321293713"},"themes":[],"title":"buy upstart","htmlText":"Buy upstart as PE ratio had drop to attractive level. Upstart is profitable and growth will be strong for the next few quarter.","listText":"Buy upstart as PE ratio had drop to attractive level. Upstart is profitable and growth will be strong for the next few quarter.","text":"Buy upstart as PE ratio had drop to attractive level. Upstart is profitable and growth will be strong for the next few quarter.","images":[],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9098229177","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3479274777284002","authorId":"3479274777284002","name":"zoomzi","avatar":"https://static.tigerbbs.com/79994bc77de771ec5e7fabc95b9d921d","crmLevel":1,"crmLevelSwitch":0,"idStr":"3479274777284002","authorIdStr":"3479274777284002"},"content":"The company is an intelligent lending platform based on cloud and AI. The platform of the company brings together consumers' demand for high-quality loans and connects it with its emerging AI banking partner network. Consumers on this platform can benefit from higher approval rates, lower interest rates and a highly automated and efficient all-digital experience. Its bank partners benefit from contacting new customers, reducing fraud and loss rates, and improving the automation of the whole loan process. To sum up, upstart is a very good company.","text":"The company is an intelligent lending platform based on cloud and AI. The platform of the company brings together consumers' demand for high-quality loans and connects it with its emerging AI banking partner network. Consumers on this platform can benefit from higher approval rates, lower interest rates and a highly automated and efficient all-digital experience. Its bank partners benefit from contacting new customers, reducing fraud and loss rates, and improving the automation of the whole loan process. To sum up, upstart is a very good company.","html":"The company is an intelligent lending platform based on cloud and AI. The platform of the company brings together consumers' demand for high-quality loans and connects it with its emerging AI banking partner network. Consumers on this platform can benefit from higher approval rates, lower interest rates and a highly automated and efficient all-digital experience. Its bank partners benefit from contacting new customers, reducing fraud and loss rates, and improving the automation of the whole loan process. To sum up, upstart is a very good company."}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":241429305721072,"gmtCreate":1699971109107,"gmtModify":1699971112632,"author":{"id":"3556663321293713","authorId":"3556663321293713","name":"kkoh","avatar":"https://static.itradeup.com/news/043182d0397ab25b04de66a4ae86820d","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3556663321293713","authorIdStr":"3556663321293713"},"themes":[],"htmlText":"Sea cannot compete with til to on shopping and thus lose money.","listText":"Sea cannot compete with til to on shopping and thus lose money.","text":"Sea cannot compete with til to on shopping and thus lose money.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/241429305721072","repostId":"1120385949","repostType":2,"repost":{"id":"1120385949","kind":"news","pubTimestamp":1700002879,"share":"https://ttm.financial/m/news/1120385949?lang=&edition=fundamental","pubTime":"2023-11-15 07:01","market":"us","language":"en","title":"Sea Stock Tumbles 22% as the Company Swings Back to Loss After New Rivals Take a Toll","url":"https://stock-news.laohu8.com/highlight/detail?id=1120385949","media":"Bloomberg","summary":"Sea Ltd : Q3 GAAP EPS of -$1.01 misses by $1.01. Revenue of $3.3B  beats by $90M.Sea stock tumbled 14% after posting fiancial results.Total gross profit was US$1.4 billion, up 17.4% year-on-year.Total net loss was US$ million, as compared to total net loss of US$ million for the third quarter of 2022.Total adjusted EBITDA1 was US$35.3 million, as compared to a loss of US$ million for the third quarter of 2022.As of September 30, 2023, cash, cash equivalents, short-term and other treasury investm","content":"<html><head></head><body><p>Sea Ltd. swung back to a loss in the third quarter, hit by flagging consumption and intensifying competition from Alibaba and TikTok on its home turf.</p><p style=\"text-align: start;\">The stock fell 22.07% on Tuesday after the company posted a net loss of $149 million, compared with a profit of $322 million the previous quarter. Southeast Asia’s largest internet firm reported a 4.9% rise in sales from a year earlier to $3.3 billion, versus the average estimate of $3.2 billion.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1a40c2774e9da0111652a2005577043a\" tg-width=\"804\" tg-height=\"624\"/></p><p>The results may stoke concerns that the US-listed company is sacrificing margins to stave off a charge from ByteDance Ltd.’s TikTok and Alibaba Group Holding Ltd.’s Lazada, or newer entrants such as PDD Holdings Inc.’s Temu. Sea plunged its most on record after founder Forrest Li declared in August his company will invest more in online retail arm Shopee and live-streaming to counter those platforms, which are appealing to younger shoppers.</p><p style=\"text-align: start;\">Till recently, Sea’s strongest markets including Indonesia seemed under siege from TikTok and a new breed of video-oriented shopping services, which used popular influencers to sell a range of wares to an engaged, growing online population. But in September, Jakarta effectively forced TikTok to shut its shopping service, acting on a growing backlash from smaller merchants against the Chinese-owned platform.</p><p style=\"text-align: start;\">Investors have been looking for clues since then on whether that abrupt exit will rekindle Sea. Before Indonesia, the market feared the Singaporean company — which reported more than a decade of losses after its 2009 founding — will sink back into the red. Compounding the situation are expectations that Southeast Asia’s internet economy will log its slowest growth on record this year, the result of an economic downturn with uncertain outcomes.</p><p style=\"text-align: start;\">Sea’s other big business, the gaming division centered around Garena, has shrunk rapidly in 2023 given a lack of new blockbuster titles. But it recently restored its marquee title Free Fire to Indian app stores after a surprise 2022 ban.</p><blockquote><p>Sea’s e-commerce revenue, driving 68% of the 1H total, should gain from Indonesian regulators’ shutdown of TikTok’s shopping platform, which faces similar risks in Malaysia. Online-shopping gross merchandise value (GMV) likely fell or stagnated in 1Q-2Q, a trend that could improve as Shopee regains lost market share from rivals amid a reacceleration in marketing spending. With Temu, the overseas arm of China’s e-tailer Pinduoduo also encroaching on Southeast Asia, such investments could intensify and cloud Sea’s net profit path. This is partially mitigated by a tepid recovery in the digital entertainment segment — driving 45% of 1H adjusted Ebitda — amid a rebound in Free Fire’s player engagement.</p><p>Free cash flow could remain under pressure amid e-commerce expansion spending. - Nathan Naidu, analyst</p></blockquote><p style=\"text-align: start;\">Li’s company had overhauled its business to focus on profitability earlier this year. Sea embarked on an aggressive cost-cutting drive to reach profit, pivoting to a focus on the bottom-line as revenue growth decelerated from the triple-digit percentage rates it enjoyed as recently as two years ago. The company froze salaries and slashed hundreds of millions of dollars in expenses to achieve positive cash flows.</p><p style=\"text-align: start;\">To jumpstart growth, Li said in August he intends to ramp up investments into e-commerce arm Shopee. He is stepping up efforts to build out its live-streaming arm, an offensive move that could erode margins and trigger a price war with TikTok and Alibaba. He argued that was necessary to defend its market share.</p><p style=\"text-align: start;\">Beyond deep-pocketed competitors Alibaba and ByteDance, local rivals such as GoTo Group are also piling the pressure on Sea. GoTo, owner of Indonesian e-commerce contender Tokopedia, almost doubled its net revenue during the June quarter.</p></body></html>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sea Stock Tumbles 22% as the Company Swings Back to Loss After New Rivals Take a Toll</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSea Stock Tumbles 22% as the Company Swings Back to Loss After New Rivals Take a Toll\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-11-15 07:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2023-11-14/singapore-s-sea-swings-back-to-loss-after-new-rivals-take-a-toll><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sea Ltd. swung back to a loss in the third quarter, hit by flagging consumption and intensifying competition from Alibaba and TikTok on its home turf.The stock fell 22.07% on Tuesday after the company...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2023-11-14/singapore-s-sea-swings-back-to-loss-after-new-rivals-take-a-toll\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SE":"Sea Ltd"},"source_url":"https://www.bloomberg.com/news/articles/2023-11-14/singapore-s-sea-swings-back-to-loss-after-new-rivals-take-a-toll","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1120385949","content_text":"Sea Ltd. swung back to a loss in the third quarter, hit by flagging consumption and intensifying competition from Alibaba and TikTok on its home turf.The stock fell 22.07% on Tuesday after the company posted a net loss of $149 million, compared with a profit of $322 million the previous quarter. Southeast Asia’s largest internet firm reported a 4.9% rise in sales from a year earlier to $3.3 billion, versus the average estimate of $3.2 billion.The results may stoke concerns that the US-listed company is sacrificing margins to stave off a charge from ByteDance Ltd.’s TikTok and Alibaba Group Holding Ltd.’s Lazada, or newer entrants such as PDD Holdings Inc.’s Temu. Sea plunged its most on record after founder Forrest Li declared in August his company will invest more in online retail arm Shopee and live-streaming to counter those platforms, which are appealing to younger shoppers.Till recently, Sea’s strongest markets including Indonesia seemed under siege from TikTok and a new breed of video-oriented shopping services, which used popular influencers to sell a range of wares to an engaged, growing online population. But in September, Jakarta effectively forced TikTok to shut its shopping service, acting on a growing backlash from smaller merchants against the Chinese-owned platform.Investors have been looking for clues since then on whether that abrupt exit will rekindle Sea. Before Indonesia, the market feared the Singaporean company — which reported more than a decade of losses after its 2009 founding — will sink back into the red. Compounding the situation are expectations that Southeast Asia’s internet economy will log its slowest growth on record this year, the result of an economic downturn with uncertain outcomes.Sea’s other big business, the gaming division centered around Garena, has shrunk rapidly in 2023 given a lack of new blockbuster titles. But it recently restored its marquee title Free Fire to Indian app stores after a surprise 2022 ban.Sea’s e-commerce revenue, driving 68% of the 1H total, should gain from Indonesian regulators’ shutdown of TikTok’s shopping platform, which faces similar risks in Malaysia. Online-shopping gross merchandise value (GMV) likely fell or stagnated in 1Q-2Q, a trend that could improve as Shopee regains lost market share from rivals amid a reacceleration in marketing spending. With Temu, the overseas arm of China’s e-tailer Pinduoduo also encroaching on Southeast Asia, such investments could intensify and cloud Sea’s net profit path. This is partially mitigated by a tepid recovery in the digital entertainment segment — driving 45% of 1H adjusted Ebitda — amid a rebound in Free Fire’s player engagement.Free cash flow could remain under pressure amid e-commerce expansion spending. - Nathan Naidu, analystLi’s company had overhauled its business to focus on profitability earlier this year. Sea embarked on an aggressive cost-cutting drive to reach profit, pivoting to a focus on the bottom-line as revenue growth decelerated from the triple-digit percentage rates it enjoyed as recently as two years ago. The company froze salaries and slashed hundreds of millions of dollars in expenses to achieve positive cash flows.To jumpstart growth, Li said in August he intends to ramp up investments into e-commerce arm Shopee. He is stepping up efforts to build out its live-streaming arm, an offensive move that could erode margins and trigger a price war with TikTok and Alibaba. He argued that was necessary to defend its market share.Beyond deep-pocketed competitors Alibaba and ByteDance, local rivals such as GoTo Group are also piling the pressure on Sea. GoTo, owner of Indonesian e-commerce contender Tokopedia, almost doubled its net revenue during the June quarter.","news_type":1},"isVote":1,"tweetType":1,"viewCount":195,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9067474560,"gmtCreate":1652503084250,"gmtModify":1676535113718,"author":{"id":"3556663321293713","authorId":"3556663321293713","name":"kkoh","avatar":"https://static.itradeup.com/news/043182d0397ab25b04de66a4ae86820d","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3556663321293713","authorIdStr":"3556663321293713"},"themes":[],"htmlText":"Buy only when inflation is peak. Yesterday is bear market rally","listText":"Buy only when inflation is peak. Yesterday is bear market rally","text":"Buy only when inflation is peak. Yesterday is bear market rally","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9067474560","repostId":"1142625526","repostType":2,"repost":{"id":"1142625526","kind":"news","pubTimestamp":1652488791,"share":"https://ttm.financial/m/news/1142625526?lang=&edition=fundamental","pubTime":"2022-05-14 08:39","market":"us","language":"en","title":"7 Tech Stocks Due for a Stunning Short Squeeze","url":"https://stock-news.laohu8.com/highlight/detail?id=1142625526","media":"investorplace","summary":"Each of these tech stocks to buy are approaching critical bounce levels.Advanced Micro Devices (AMD)","content":"<html><head></head><body><ul><li>Each of these tech stocks to buy are approaching critical bounce levels.</li><li>Advanced Micro Devices (AMD) stock is hot and cheap.</li><li>Nvidia (NVDA) is the new trend-setter.</li><li>Intel (INTC) is s dirt cheap tech behemoth.</li><li>Microsoft (MSFT) represents the most improved old dog on the Street.</li><li>Tesla (TSLA) continues to lead the electric vehicle space.</li><li>Shopify (SHOP) is reinventing the world Amazon created.</li><li>Amazon (AMZN) is a titan that continues to make great moves.</li></ul><p>Wall Street is a total mess this week, but the list of tech stocks to buy remains quite large. Equities and other asset classes are in free fall. Even Bitcoin (BTC-USD) is now below $30,000. The tech stocks I’ve identified today are all likely to experience sharp recoveries soon enough.</p><p>We should recognize that there are short-term risks, like yesterday the indices fell 2.5%. More proof of the chaos is that the CBOE volatility index (INDEXCBOE:VIX) also closed red. Since bond yields also fell, we should not blame the inflation report. Regardless, most companies are still reporting strong P&amp;L’s. Even Upstart (NASDAQ:UPST) collapsed despite growing sales 150%. Risk appetite is very particular these days, and investors favor less frothy tickers.</p><p>I limited my list of tech stocks to include nothing but outstanding companies. The uneasiness in the stock market will abate after a while, as the hawkish Federal Reserve rhetoric becomes stale. Meanwhile, the indices have room to fall another 12% to 20% from here. Therefore, tech stocks may not have hit an absolute bottom. So it would be a wise to throttle deployment of new trades.</p><p>Long term, the overwhelming bullish thesis is that the world is absolutely going digital.  This is a one-way trend and we will need smart machines to make that happen. Overall, demand for these products and services will linger for a decade.</p><p><img src=\"https://static.tigerbbs.com/ab339ae06fbe3e2c4f403220172a7381\" tg-width=\"1117\" tg-height=\"447\" width=\"100%\" height=\"auto\"/></p><h2>Advanced Micro Devices (AMD)</h2><p>I will start with a successful company that provides brains to the operations. The world needs computers and Advanced Micro Devices (NASDAQ:AMD) provides strong processing power to make that happen. The company’s fundamentals are excellent, and it’s relatively cheap. Its reputation has grown to the point that it has staunch fans. I, for one, have recently purchased two computers with AMD internals.</p><p>The stock chart is approaching a support zone above $75 per share. There are likely to be bulls lurking there waiting to buy it. This has served as a base since summer of 2020. However, investors should look out for small technical hiccups to close a few gaps below that. Below these levels, AMD would make for an excellent value proposition. The rally back should be violent, because Wall Street habitually overdoes things. The bears cannot help but overstay their welcome into winning trades.</p><h2>Nvidia (NVDA)</h2><p>Nvidia (NASDAQ:NVDA) stock is suffering a similar fate to AMD. It is its chief headline rival also providing excellent brains to our highly technical world. Nvidia has earned the reputation of the lead innovator in the field. Their financial results support these claims with absolute certainty. Nvidia management grew its revenues more than five times since 2015. They even boast a $10 billion net income. Last year they generated $9 billion in cash from their operations.</p><p>However, the stock is not cheap, especially relative to its competition. With a price-to-sales ratio of 17x, it could lose a bit of froth to bring that more in line. Nevertheless, the stock is also falling into a sharp pivotal zone. The support extends from current price through $138 per share. Those levels have been in contention also since 2020, so they will provide support.</p><p>This stock is also in a bearish pattern that may have a few more bucks to go. All it needs is for the indices to stabilize and it will too. There’s no doubt of Nvidia’s excellence, and the buyers will come back to it with force. The rally back should be more violent than the sellers may yet realize.</p><h2>Intel (INTC)</h2><p>While Nvidia and AMD hog the headlines, Intel is still the behemoth they are both chasing. Most investors don’t realize that Intel (NASDAQ:INTC) is larger than the other two twice over. It is still a beast, but not as exciting. Eventually they recapture the investor imagination and earn back the respect they lost. Fundamentally this is the cheapest of them all by a mile.</p><p>From a charts perspective, INTC stock has had strong support around $40 per share since 2018. Investors who hold the stock have strong hands. They are not likely to capitulate easily. There is technical risk just like the other two, but it’s likely to find support soon. The rally back in this one may not be as ferocious as the other two. This makes it carry a bit less risk over all.</p><h2>Microsoft (MSFT)</h2><p>Microsoft (NASDAQ:MSFT) is an old dog that lived through the dot com bubble. MSFT stock has lost 25% of its value since the high it set last fall. Since it lost the support from early March, it could even overshoot a bit lower from here. But if the indices stabilize, Microsoft has technical reasons to rally back 15% and quickly.</p><p>This company proved itself worthy of trust. Microsoft was able to shift a giant ship and steer it straight into winning trends. Under the leadership of Satya Nadella, the company made it look easy too. Wall Street rewarded MSFT for its efforts, as the stock still is miles away from its pandemic lows. While it is not cheap, there isn’t obvious bloat either. Revenues for the trailing 12 months doubled from five years ago. With a net income of $70 billion, investors can sit through a few bumps along the way. If I were long the stock I can confidently wait out these jitters.</p><h2>Tesla (TSLA)</h2><p>While you might not see electric vehicle maker Tesla (NASDAQ:TSLA) as a tech stock, it’s full of technology, so I’m keeping it on this list. Currently its financials are impeccable and twice as efficient with its gross margin compared to Ford (NYSE:F) or General Motors (NYSE:GM).</p><p>Tesla stock is a bigger beast than the company itself. Over time it has slayed many shorts. Not yesterday though, as it fell 8% and for no specific reason. However it is still doing relatively better than the indices. At least it has not yet lost its support from Feb. 24. But therein lies some technical risk. If TSLA falls below $697 per share, it could accelerate lower.</p><p>I am confident that once it stabilizes Tesla will slay more bears. The rally back will be ferocious, so investors should avoid shorting it. Smart money would look for entries near support spots below. It too will need help from the overall markets.</p><h2>Shopify (SHOP)</h2><p>The line between tech and retail companies is paper thin. Therefore, I’m including Shopify (NYSE:SHOP) in my list of tech stocks to buy. If there is a stock that can rally fast, SHOP stock is it. Unfortunately it does so in both directions. Case in point, the company just lost 80% of its value since last November. Luckily it had just rallied over 200% out of the pandemic.</p><p>SHOP stock took a long round trip road to $1,760 and closed under $320 on Wednesday. Investors drove it straight into the pandemic base. Once it comes back into style, the buyers will overdo it one more time. It is hard to quantify the size of the rebound, as it is hard to pinpoint the absolute bottom. Therefore, taking small bites is best.</p><p>Management grew revenues seven-fold in five years. And they did that without creating excessive valuation. Its humble price-to-sales suggests that owners now have realistic expectations. Moderation is an extremely important virtue when dealing with Shopify stock.</p><h2>Amazon (AMZN)</h2><p>If we include SHOP, then Amazon (NASDAQ:AMZN) also belongs on this list. After all, Amazon essentially owns the cloud, so most tech-related things pass through their servers.</p><p>It too has had a bad time on Wall Street of late. Amazon stock is 44% below its all-time highs. It is also approaching a very sharp consolidation zone. Unfortunately it is also wide, so the floor is more of a band of support. Going all-in to catch this falling machete would be reckless.</p><p>Its fundamentals are beyond reproach and its financial metrics are strong. Amazon generates $470 billion in revenues and $20 billion in net income. It has 1the means to do whatever it wants to grow the business further. The team is rarely short on imagination and it has earned every benefit of the doubt. This is a tech stock I could own for a lifetime.</p></body></html>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>7 Tech Stocks Due for a Stunning Short Squeeze</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n7 Tech Stocks Due for a Stunning Short Squeeze\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-14 08:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2022/05/7-tech-stocks-due-for-a-stunning-short-squeeze/><strong>investorplace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Each of these tech stocks to buy are approaching critical bounce levels.Advanced Micro Devices (AMD) stock is hot and cheap.Nvidia (NVDA) is the new trend-setter.Intel (INTC) is s dirt cheap tech ...</p>\n\n<a href=\"https://investorplace.com/2022/05/7-tech-stocks-due-for-a-stunning-short-squeeze/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MSFT":"微软","AMD":"美国超微公司","NVDA":"英伟达","SHOP":"Shopify Inc","TSLA":"特斯拉","AMZN":"亚马逊","INTC":"英特尔"},"source_url":"https://investorplace.com/2022/05/7-tech-stocks-due-for-a-stunning-short-squeeze/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1142625526","content_text":"Each of these tech stocks to buy are approaching critical bounce levels.Advanced Micro Devices (AMD) stock is hot and cheap.Nvidia (NVDA) is the new trend-setter.Intel (INTC) is s dirt cheap tech behemoth.Microsoft (MSFT) represents the most improved old dog on the Street.Tesla (TSLA) continues to lead the electric vehicle space.Shopify (SHOP) is reinventing the world Amazon created.Amazon (AMZN) is a titan that continues to make great moves.Wall Street is a total mess this week, but the list of tech stocks to buy remains quite large. Equities and other asset classes are in free fall. Even Bitcoin (BTC-USD) is now below $30,000. The tech stocks I’ve identified today are all likely to experience sharp recoveries soon enough.We should recognize that there are short-term risks, like yesterday the indices fell 2.5%. More proof of the chaos is that the CBOE volatility index (INDEXCBOE:VIX) also closed red. Since bond yields also fell, we should not blame the inflation report. Regardless, most companies are still reporting strong P&L’s. Even Upstart (NASDAQ:UPST) collapsed despite growing sales 150%. Risk appetite is very particular these days, and investors favor less frothy tickers.I limited my list of tech stocks to include nothing but outstanding companies. The uneasiness in the stock market will abate after a while, as the hawkish Federal Reserve rhetoric becomes stale. Meanwhile, the indices have room to fall another 12% to 20% from here. Therefore, tech stocks may not have hit an absolute bottom. So it would be a wise to throttle deployment of new trades.Long term, the overwhelming bullish thesis is that the world is absolutely going digital.  This is a one-way trend and we will need smart machines to make that happen. Overall, demand for these products and services will linger for a decade.Advanced Micro Devices (AMD)I will start with a successful company that provides brains to the operations. The world needs computers and Advanced Micro Devices (NASDAQ:AMD) provides strong processing power to make that happen. The company’s fundamentals are excellent, and it’s relatively cheap. Its reputation has grown to the point that it has staunch fans. I, for one, have recently purchased two computers with AMD internals.The stock chart is approaching a support zone above $75 per share. There are likely to be bulls lurking there waiting to buy it. This has served as a base since summer of 2020. However, investors should look out for small technical hiccups to close a few gaps below that. Below these levels, AMD would make for an excellent value proposition. The rally back should be violent, because Wall Street habitually overdoes things. The bears cannot help but overstay their welcome into winning trades.Nvidia (NVDA)Nvidia (NASDAQ:NVDA) stock is suffering a similar fate to AMD. It is its chief headline rival also providing excellent brains to our highly technical world. Nvidia has earned the reputation of the lead innovator in the field. Their financial results support these claims with absolute certainty. Nvidia management grew its revenues more than five times since 2015. They even boast a $10 billion net income. Last year they generated $9 billion in cash from their operations.However, the stock is not cheap, especially relative to its competition. With a price-to-sales ratio of 17x, it could lose a bit of froth to bring that more in line. Nevertheless, the stock is also falling into a sharp pivotal zone. The support extends from current price through $138 per share. Those levels have been in contention also since 2020, so they will provide support.This stock is also in a bearish pattern that may have a few more bucks to go. All it needs is for the indices to stabilize and it will too. There’s no doubt of Nvidia’s excellence, and the buyers will come back to it with force. The rally back should be more violent than the sellers may yet realize.Intel (INTC)While Nvidia and AMD hog the headlines, Intel is still the behemoth they are both chasing. Most investors don’t realize that Intel (NASDAQ:INTC) is larger than the other two twice over. It is still a beast, but not as exciting. Eventually they recapture the investor imagination and earn back the respect they lost. Fundamentally this is the cheapest of them all by a mile.From a charts perspective, INTC stock has had strong support around $40 per share since 2018. Investors who hold the stock have strong hands. They are not likely to capitulate easily. There is technical risk just like the other two, but it’s likely to find support soon. The rally back in this one may not be as ferocious as the other two. This makes it carry a bit less risk over all.Microsoft (MSFT)Microsoft (NASDAQ:MSFT) is an old dog that lived through the dot com bubble. MSFT stock has lost 25% of its value since the high it set last fall. Since it lost the support from early March, it could even overshoot a bit lower from here. But if the indices stabilize, Microsoft has technical reasons to rally back 15% and quickly.This company proved itself worthy of trust. Microsoft was able to shift a giant ship and steer it straight into winning trends. Under the leadership of Satya Nadella, the company made it look easy too. Wall Street rewarded MSFT for its efforts, as the stock still is miles away from its pandemic lows. While it is not cheap, there isn’t obvious bloat either. Revenues for the trailing 12 months doubled from five years ago. With a net income of $70 billion, investors can sit through a few bumps along the way. If I were long the stock I can confidently wait out these jitters.Tesla (TSLA)While you might not see electric vehicle maker Tesla (NASDAQ:TSLA) as a tech stock, it’s full of technology, so I’m keeping it on this list. Currently its financials are impeccable and twice as efficient with its gross margin compared to Ford (NYSE:F) or General Motors (NYSE:GM).Tesla stock is a bigger beast than the company itself. Over time it has slayed many shorts. Not yesterday though, as it fell 8% and for no specific reason. However it is still doing relatively better than the indices. At least it has not yet lost its support from Feb. 24. But therein lies some technical risk. If TSLA falls below $697 per share, it could accelerate lower.I am confident that once it stabilizes Tesla will slay more bears. The rally back will be ferocious, so investors should avoid shorting it. Smart money would look for entries near support spots below. It too will need help from the overall markets.Shopify (SHOP)The line between tech and retail companies is paper thin. Therefore, I’m including Shopify (NYSE:SHOP) in my list of tech stocks to buy. If there is a stock that can rally fast, SHOP stock is it. Unfortunately it does so in both directions. Case in point, the company just lost 80% of its value since last November. Luckily it had just rallied over 200% out of the pandemic.SHOP stock took a long round trip road to $1,760 and closed under $320 on Wednesday. Investors drove it straight into the pandemic base. Once it comes back into style, the buyers will overdo it one more time. It is hard to quantify the size of the rebound, as it is hard to pinpoint the absolute bottom. Therefore, taking small bites is best.Management grew revenues seven-fold in five years. And they did that without creating excessive valuation. Its humble price-to-sales suggests that owners now have realistic expectations. Moderation is an extremely important virtue when dealing with Shopify stock.Amazon (AMZN)If we include SHOP, then Amazon (NASDAQ:AMZN) also belongs on this list. After all, Amazon essentially owns the cloud, so most tech-related things pass through their servers.It too has had a bad time on Wall Street of late. Amazon stock is 44% below its all-time highs. It is also approaching a very sharp consolidation zone. Unfortunately it is also wide, so the floor is more of a band of support. Going all-in to catch this falling machete would be reckless.Its fundamentals are beyond reproach and its financial metrics are strong. Amazon generates $470 billion in revenues and $20 billion in net income. It has 1the means to do whatever it wants to grow the business further. The team is rarely short on imagination and it has earned every benefit of the doubt. This is a tech stock I could own for a lifetime.","news_type":1},"isVote":1,"tweetType":1,"viewCount":106,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":292702305870072,"gmtCreate":1712486960172,"gmtModify":1712486963677,"author":{"id":"3556663321293713","authorId":"3556663321293713","name":"kkoh","avatar":"https://static.itradeup.com/news/043182d0397ab25b04de66a4ae86820d","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3556663321293713","authorIdStr":"3556663321293713"},"themes":[],"htmlText":"Great article, would you like to share it?","listText":"Great article, would you like to share it?","text":"Great article, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/292702305870072","repostId":"2425319145","repostType":2,"repost":{"id":"2425319145","kind":"highlight","pubTimestamp":1712307780,"share":"https://ttm.financial/m/news/2425319145?lang=&edition=fundamental","pubTime":"2024-04-05 17:03","market":"fut","language":"en","title":"Better Growth Biotech Buy: Iovance Biotherapeutics vs CRISPR Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2425319145","media":"Motley Fool","summary":"These companies are in the early days of their growth stories.","content":"<html><body><ul>\n<li>\n<div>\n<svg fill=\"none\" height=\"15\" viewbox=\"0 0 14 15\" width=\"14\" xmlns=\"http://www.w3.org/2000/svg\">\n<path d=\"M14 5.58984C14 2.91016 11.8398 0.75 9.16016 0.75C6.50781 0.777344 4.375 2.91016 4.375 5.5625C4.375 6.10938 4.45703 6.60156 4.59375 7.09375L0.191406 11.4961C0.0546875 11.6328 0 11.7969 0 11.9609V14.0938C0 14.4766 0.273438 14.75 0.65625 14.75H3.71875C4.07422 14.75 4.375 14.4766 4.375 14.0938V13H5.46875C5.82422 13 6.125 12.7266 6.125 12.3438V11.25H7.13672C7.30078 11.25 7.51953 11.168 7.62891 11.0312L8.28516 10.293C8.55859 10.3477 8.85938 10.375 9.1875 10.375C11.8398 10.375 14 8.24219 14 5.58984ZM9.1875 4.25C9.1875 3.53906 9.76172 2.9375 10.5 2.9375C11.2109 2.9375 11.8125 3.53906 11.8125 4.25C11.8125 4.98828 11.2109 5.5625 10.5 5.5625C9.76172 5.5625 9.1875 4.98828 9.1875 4.25Z\" fill=\"#FFB81C\"></path>\n</svg>\n</div>\n<div>Both of these companies recently won regulatory approval for their first products.</div>\n</li>\n<li>\n<div>\n<svg fill=\"none\" height=\"15\" viewbox=\"0 0 14 15\" width=\"14\" xmlns=\"http://www.w3.org/2000/svg\">\n<path d=\"M14 5.58984C14 2.91016 11.8398 0.75 9.16016 0.75C6.50781 0.777344 4.375 2.91016 4.375 5.5625C4.375 6.10938 4.45703 6.60156 4.59375 7.09375L0.191406 11.4961C0.0546875 11.6328 0 11.7969 0 11.9609V14.0938C0 14.4766 0.273438 14.75 0.65625 14.75H3.71875C4.07422 14.75 4.375 14.4766 4.375 14.0938V13H5.46875C5.82422 13 6.125 12.7266 6.125 12.3438V11.25H7.13672C7.30078 11.25 7.51953 11.168 7.62891 11.0312L8.28516 10.293C8.55859 10.3477 8.85938 10.375 9.1875 10.375C11.8398 10.375 14 8.24219 14 5.58984ZM9.1875 4.25C9.1875 3.53906 9.76172 2.9375 10.5 2.9375C11.2109 2.9375 11.8125 3.53906 11.8125 4.25C11.8125 4.98828 11.2109 5.5625 10.5 5.5625C9.76172 5.5625 9.1875 4.98828 9.1875 4.25Z\" fill=\"#FFB81C\"></path>\n</svg>\n</div>\n<div>Both Iovance Biotherapeutics and CRISPR <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> have developed game-changing treatment technologies.</div>\n</li>\n</ul><div><p>If you're looking to add some growth to your portfolio, a great way to do it is by picking up shares of a biotech company with a recently approved product. Such a treatment will represent a brand new revenue driver for the company -- and sometimes, even its first one -- so if the product takes off, the share price may follow. In many cases, this marks the very start of the biotech's growth story, allowing you to get in early and benefit over time.</p><p>This is the case for <strong>Iovance Biotherapeutics</strong> <span>(IOVA<span> -2.93%</span>)</span> and <strong>CRISPR Therapeutics</strong> <span>(CRSP<span> 0.71%</span>)</span> today. Each of these biotech players recently won approval for its first product -- and these aren't only regulatory victories, but also votes of confidence in the game-changing technologies they have developed. These stocks both represent interesting growth opportunities today. But if you could only choose one to add to your portfolio, which would be the better buy?</p><div><img loading=\"lazy\" src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F771808%2Fgettyimages-research-team-smiles-in-lab.jpg&amp;op=resize&amp;w=700\" srcset=\"https://g.foolcdn.com/image/?url=https%3A//g.foolcdn.com/editorial/images/771808/gettyimages-research-team-smiles-in-lab.jpg&amp;w=300&amp;op=resize 300w, https://g.foolcdn.com/image/?url=https%3A//g.foolcdn.com/editorial/images/771808/gettyimages-research-team-smiles-in-lab.jpg&amp;w=1000&amp;op=resize 1000w, https://g.foolcdn.com/image/?url=https%3A//g.foolcdn.com/editorial/images/771808/gettyimages-research-team-smiles-in-lab.jpg&amp;w=2000&amp;op=resize 2000w\"/><p>Image source: Getty Images.</p></div><h2>The case for Iovance</h2><p>Iovance recently won accelerated approval for Amtagvi, generically known as lifileucel, a treatment for advanced melanoma -- the most dangerous form of skin cancer. The biotech company has developed an exciting technology that harnesses the power of the patient's own immune system to attack their cancer. To produce Amtagvi, doctors collect tumor-infiltrating lymphocytes (TILs) -- in simple terms, cells that fight cancer -- from the specific patient's tumor. These are then sent to Iovance, which uses them to grow billions more of those same effective cancer-fighting cells, which are then infused back into the patient.</p><div><app :collapse_on_load=\"false\" :instrument_id=\"339444\" :show_benchmark_compare=\"false\" amount_change=\"-0.41\" average_volume=\"9,643,902\" company_name=\"Iovance Biotherapeutics\" current_price=\"13.60\" daily_high=\"14.21\" daily_low=\"13.40\" default_period=\"OneYear\" dividend_yield=\"N/A\" exchange=\"NASDAQ\" fifty_two_week_high=\"18.33\" fifty_two_week_low=\"3.21\" gross_margin=\"-3091.17\" logo=\"https://g.foolcdn.com/art/companylogos/mark/IOVA.png\" market_cap=\"$4B\" pe_ratio=\"-7.18\" percent_change=\"-2.93\" symbol=\"IOVA\" volume=\"3\"></app></div><p>The Amtagvi nod represents the first Food and Drug Administration approval for a one-time, personalized T-cell therapy for a solid tumor cancer. More than 30 authorized treatment centers now are ready to begin delivering it, and Iovance's manufacturing capacity can accommodate several thousand patients annually. The company also has many TIL candidates and TIL combinations with other treatments involved in clinical trials, including a trial in non-small cell lung cancer that may support a regulatory request.</p><p>This year, Iovance should start to collect some revenue from its first TIL product, and this may be just the beginning.</p><div><div></div></div><h2>The case for CRISPR Therapeutics</h2><p>CRISPR Therapeutics specializes in gene-editing therapies based on CRISPR technology. Certain diseases are caused by mutations in a single section of people's genetic code. CRISPR technology uses a natural cellular process to cut a patient's DNA at highly specific locations and insert a new sequence that corrects the faulty mutation that's causing their disease.</p><p>Late last year, CRISPR Therapeutics won the world's first-ever regulatory approval for a product based on CRISPR technology -- Casgevy, a treatment for the blood disorders sickle cell disease and beta-thalassemia.</p><div><app :collapse_on_load=\"false\" :instrument_id=\"338676\" :show_benchmark_compare=\"false\" amount_change=\"0.46\" average_volume=\"1,897,450\" company_name=\"CRISPR Therapeutics\" current_price=\"65.06\" daily_high=\"67.25\" daily_low=\"64.67\" default_period=\"OneYear\" dividend_yield=\"N/A\" exchange=\"NASDAQ\" fifty_two_week_high=\"91.10\" fifty_two_week_low=\"37.55\" gross_margin=\"65.88\" logo=\"https://g.foolcdn.com/art/companylogos/mark/CRSP.png\" market_cap=\"$5B\" pe_ratio=\"-33.01\" percent_change=\"0.71\" symbol=\"CRSP\" volume=\"105\"></app></div><p>The exciting thing about Casgevy and the company's other CRISPR candidates is they represent one-time treatments that (if effective) act as functional cures. This clearly could drive patients to give them a try, especially in diseases with limited treatment options -- like sickle cell disease and beta-thalassemia.</p><p>As for what's ahead, CRISPR Therapeutics has immuno-oncology candidates involved in clinical trials, and aims to launch its first trial in the area of autoimmune diseases in the first half with a candidate to treat systemic lupus erythematosus.</p><div><div></div></div><p>So, like Iovance, CRISPR Therapeutics should start to deliver product revenue this year, and we also should expect clinical trial progress from its pipeline candidates.</p><h2>Iovance or CRISPR Therapeutics?</h2><p>Choosing between Iovance and CRISPR Therapeutics is tough because both of these companies are launching their first products and advancing their pipelines. And each of these stocks has momentum: Iovance has soared by a triple-digit percentage over the past year, and CRISPR Therapeutics is up by close to 50%. But one looks financially stronger, making it the better buy right now.</p><p>CRISPR Therapeutics has a cash position of more than $2.1 billion and has reported some quarters of profitability thanks to collaboration revenue. Iovance has a cash level of about $485 million, up from December thanks to a follow-on round of equity financing. Management expects this and its potential revenue to fund operations through the second half of next year. As for earnings, Iovance's losses have deepened over time.</p><p>This wouldn't drive me away from Iovance, because I do think the company could have a bright future. But if I had to choose between these two stocks right now, I would go for CRISPR Therapeutics because it not only offers solid earnings growth prospects, it also has the financial strength to keep its pipeline momentum going.</p><div></div></div></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Better Growth Biotech Buy: Iovance Biotherapeutics vs CRISPR Therapeutics</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBetter Growth Biotech Buy: Iovance Biotherapeutics vs CRISPR Therapeutics\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-05 17:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2024/04/05/better-growth-biotech-buy-iovance-vs-crispr-therap/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Both of these companies recently won regulatory approval for their first products.\n\n\n\n\n\n\n\nBoth Iovance Biotherapeutics and CRISPR Therapeutics have developed game-changing treatment technologies.\n\nIf ...</p>\n\n<a href=\"https://www.fool.com/investing/2024/04/05/better-growth-biotech-buy-iovance-vs-crispr-therap/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F771808%2Fgettyimages-research-team-smiles-in-lab.jpg&op=resize&w=165&h=104","relate_stocks":{"LU1861558580.USD":"日兴方舟颠覆性创新基金B","LENZ":"Therapeutics","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","CRSP":"CRISPR Therapeutics AG","BK4585":"ETF&股票定投概念","BK4556":"基因编辑","BK4139":"生物科技","BK4588":"碎股"},"source_url":"https://www.fool.com/investing/2024/04/05/better-growth-biotech-buy-iovance-vs-crispr-therap/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2425319145","content_text":"Both of these companies recently won regulatory approval for their first products.\n\n\n\n\n\n\n\nBoth Iovance Biotherapeutics and CRISPR Therapeutics have developed game-changing treatment technologies.\n\nIf you're looking to add some growth to your portfolio, a great way to do it is by picking up shares of a biotech company with a recently approved product. Such a treatment will represent a brand new revenue driver for the company -- and sometimes, even its first one -- so if the product takes off, the share price may follow. In many cases, this marks the very start of the biotech's growth story, allowing you to get in early and benefit over time.This is the case for Iovance Biotherapeutics (IOVA -2.93%) and CRISPR Therapeutics (CRSP 0.71%) today. Each of these biotech players recently won approval for its first product -- and these aren't only regulatory victories, but also votes of confidence in the game-changing technologies they have developed. These stocks both represent interesting growth opportunities today. But if you could only choose one to add to your portfolio, which would be the better buy?Image source: Getty Images.The case for IovanceIovance recently won accelerated approval for Amtagvi, generically known as lifileucel, a treatment for advanced melanoma -- the most dangerous form of skin cancer. The biotech company has developed an exciting technology that harnesses the power of the patient's own immune system to attack their cancer. To produce Amtagvi, doctors collect tumor-infiltrating lymphocytes (TILs) -- in simple terms, cells that fight cancer -- from the specific patient's tumor. These are then sent to Iovance, which uses them to grow billions more of those same effective cancer-fighting cells, which are then infused back into the patient.The Amtagvi nod represents the first Food and Drug Administration approval for a one-time, personalized T-cell therapy for a solid tumor cancer. More than 30 authorized treatment centers now are ready to begin delivering it, and Iovance's manufacturing capacity can accommodate several thousand patients annually. The company also has many TIL candidates and TIL combinations with other treatments involved in clinical trials, including a trial in non-small cell lung cancer that may support a regulatory request.This year, Iovance should start to collect some revenue from its first TIL product, and this may be just the beginning.The case for CRISPR TherapeuticsCRISPR Therapeutics specializes in gene-editing therapies based on CRISPR technology. Certain diseases are caused by mutations in a single section of people's genetic code. CRISPR technology uses a natural cellular process to cut a patient's DNA at highly specific locations and insert a new sequence that corrects the faulty mutation that's causing their disease.Late last year, CRISPR Therapeutics won the world's first-ever regulatory approval for a product based on CRISPR technology -- Casgevy, a treatment for the blood disorders sickle cell disease and beta-thalassemia.The exciting thing about Casgevy and the company's other CRISPR candidates is they represent one-time treatments that (if effective) act as functional cures. This clearly could drive patients to give them a try, especially in diseases with limited treatment options -- like sickle cell disease and beta-thalassemia.As for what's ahead, CRISPR Therapeutics has immuno-oncology candidates involved in clinical trials, and aims to launch its first trial in the area of autoimmune diseases in the first half with a candidate to treat systemic lupus erythematosus.So, like Iovance, CRISPR Therapeutics should start to deliver product revenue this year, and we also should expect clinical trial progress from its pipeline candidates.Iovance or CRISPR Therapeutics?Choosing between Iovance and CRISPR Therapeutics is tough because both of these companies are launching their first products and advancing their pipelines. And each of these stocks has momentum: Iovance has soared by a triple-digit percentage over the past year, and CRISPR Therapeutics is up by close to 50%. But one looks financially stronger, making it the better buy right now.CRISPR Therapeutics has a cash position of more than $2.1 billion and has reported some quarters of profitability thanks to collaboration revenue. Iovance has a cash level of about $485 million, up from December thanks to a follow-on round of equity financing. Management expects this and its potential revenue to fund operations through the second half of next year. As for earnings, Iovance's losses have deepened over time.This wouldn't drive me away from Iovance, because I do think the company could have a bright future. But if I had to choose between these two stocks right now, I would go for CRISPR Therapeutics because it not only offers solid earnings growth prospects, it also has the financial strength to keep its pipeline momentum going.","news_type":1},"isVote":1,"tweetType":1,"viewCount":204,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9058550456,"gmtCreate":1654868221175,"gmtModify":1676535525318,"author":{"id":"3556663321293713","authorId":"3556663321293713","name":"kkoh","avatar":"https://static.itradeup.com/news/043182d0397ab25b04de66a4ae86820d","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3556663321293713","authorIdStr":"3556663321293713"},"themes":[],"htmlText":"Us&nbsp; headline inflation is 8 6%. High inflation does not bode well for tech stock. NO wonder focusing and all tech stock drop today","listText":"Us&nbsp; headline inflation is 8 6%. High inflation does not bode well for tech stock. NO wonder focusing and all tech stock drop today","text":"Us headline inflation is 8 6%. High inflation does not bode well for tech stock. NO wonder focusing and all tech stock drop today","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9058550456","repostId":"1179770116","repostType":4,"repost":{"id":"1179770116","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1654849697,"share":"https://ttm.financial/m/news/1179770116?lang=&edition=fundamental","pubTime":"2022-06-10 16:28","market":"us","language":"en","title":"DocuSign Stock Tumbled 24% in Premarket Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1179770116","media":"Tiger Newspress","summary":"DocuSign reported earnings that missed expectations for the April quarter, sending the stock lower i","content":"<html><head></head><body><p><a href=\"https://laohu8.com/S/DOCU\">DocuSign</a> reported earnings that missed expectations for the April quarter, sending the stock lower in premarket trading.</p><p>The electronic signature documents company reported fiscal first-quarter adjusted earnings per share of 38 cents, compared with Wall Street&#39;s consensus estimate of 46 cents, according to FactSet. Revenue came in at $589 million, which was slightly above analysts&#39; expectations of $583 million. DocuSign also gave a guidance range of between $600 million to $604 million for the current quarter versus the $601 million consensus.<img src=\"https://static.tigerbbs.com/832ac4cdc3514845d41e0f475e2563c8\" tg-width=\"843\" tg-height=\"675\" width=\"100%\" height=\"auto\"/>&#34;With over a billion users worldwide, the proven value of our products, and the significant opportunity we have ahead of us, we&#39;re confident in our ability to successfully navigate the challenges of a dynamic global environment,&#34; Dan Springer, CEO of DocuSign, said in a statement.</p><p>Earlier this year, DocuSign had provided an outlook that disappointed Wall Street.</p><p>Wall Street analysts have been mixed on DocuSign. About 50% have ratings of Buy or the equivalent on the stock, while roughly 45% have Hold ratings on the shares, according to FactSet.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>DocuSign Stock Tumbled 24% in Premarket Trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDocuSign Stock Tumbled 24% in Premarket Trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-06-10 16:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p><a href=\"https://laohu8.com/S/DOCU\">DocuSign</a> reported earnings that missed expectations for the April quarter, sending the stock lower in premarket trading.</p><p>The electronic signature documents company reported fiscal first-quarter adjusted earnings per share of 38 cents, compared with Wall Street&#39;s consensus estimate of 46 cents, according to FactSet. Revenue came in at $589 million, which was slightly above analysts&#39; expectations of $583 million. DocuSign also gave a guidance range of between $600 million to $604 million for the current quarter versus the $601 million consensus.<img src=\"https://static.tigerbbs.com/832ac4cdc3514845d41e0f475e2563c8\" tg-width=\"843\" tg-height=\"675\" width=\"100%\" height=\"auto\"/>&#34;With over a billion users worldwide, the proven value of our products, and the significant opportunity we have ahead of us, we&#39;re confident in our ability to successfully navigate the challenges of a dynamic global environment,&#34; Dan Springer, CEO of DocuSign, said in a statement.</p><p>Earlier this year, DocuSign had provided an outlook that disappointed Wall Street.</p><p>Wall Street analysts have been mixed on DocuSign. About 50% have ratings of Buy or the equivalent on the stock, while roughly 45% have Hold ratings on the shares, according to FactSet.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DOCU":"Docusign"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1179770116","content_text":"DocuSign reported earnings that missed expectations for the April quarter, sending the stock lower in premarket trading.The electronic signature documents company reported fiscal first-quarter adjusted earnings per share of 38 cents, compared with Wall Street's consensus estimate of 46 cents, according to FactSet. Revenue came in at $589 million, which was slightly above analysts' expectations of $583 million. DocuSign also gave a guidance range of between $600 million to $604 million for the current quarter versus the $601 million consensus.\"With over a billion users worldwide, the proven value of our products, and the significant opportunity we have ahead of us, we're confident in our ability to successfully navigate the challenges of a dynamic global environment,\" Dan Springer, CEO of DocuSign, said in a statement.Earlier this year, DocuSign had provided an outlook that disappointed Wall Street.Wall Street analysts have been mixed on DocuSign. About 50% have ratings of Buy or the equivalent on the stock, while roughly 45% have Hold ratings on the shares, according to FactSet.","news_type":1},"isVote":1,"tweetType":1,"viewCount":288,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9019406573,"gmtCreate":1648616899754,"gmtModify":1676534365973,"author":{"id":"3556663321293713","authorId":"3556663321293713","name":"kkoh","avatar":"https://static.itradeup.com/news/043182d0397ab25b04de66a4ae86820d","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3556663321293713","authorIdStr":"3556663321293713"},"themes":[],"htmlText":"Quantumscape had a strong moat. So far 4 company had tested using quantumscape battery cell.","listText":"Quantumscape had a strong moat. So far 4 company had tested using quantumscape battery cell.","text":"Quantumscape had a strong moat. So far 4 company had tested using quantumscape battery cell.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9019406573","repostId":"1149825957","repostType":2,"repost":{"id":"1149825957","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1648541504,"share":"https://ttm.financial/m/news/1149825957?lang=&edition=fundamental","pubTime":"2022-03-29 16:11","market":"us","language":"en","title":"QuantumScape Stock Climbed 2% in Premarket Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1149825957","media":"Tiger Newspress","summary":"QuantumScape stock climbed 2% in premarket trading as QuantumScape's relation with Volkswagen could ","content":"<html><head></head><body><p>QuantumScape stock climbed 2% in premarket trading as QuantumScape&#39;s relation with Volkswagen could deepen further.</p><p><img src=\"https://static.tigerbbs.com/b02c0c6314ab8182d99cbe693baaaa26\" tg-width=\"841\" tg-height=\"620\" width=\"100%\" height=\"auto\"/></p><p>According to the <i>Manager Magazin</i> article<i>,</i><b>Volkswagen</b>&#39;s luxury brand Porsche, best known for its 911 sports car, is reportedly developing an electric version of the 911 that could use solid-state batteries, and is working with QuantumScape to supply them.</p><p>Although neither QuantumScape nor Porsche have confirmed anything yet, investors were perhaps betting on this rumor proving  true, given the company&#39;s long-standing partnership with Volkswagen.</p><p>In 2021, QuantumScape received an additional $100 million worth of funding from Volkswagen after its battery cells met the automaker&#39;s technical milestone requirements in lab tests. The two companies have also signed an agreement to jointly develop a solid-state battery pilot-line facility.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>QuantumScape Stock Climbed 2% in Premarket Trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nQuantumScape Stock Climbed 2% in Premarket Trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-03-29 16:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>QuantumScape stock climbed 2% in premarket trading as QuantumScape&#39;s relation with Volkswagen could deepen further.</p><p><img src=\"https://static.tigerbbs.com/b02c0c6314ab8182d99cbe693baaaa26\" tg-width=\"841\" tg-height=\"620\" width=\"100%\" height=\"auto\"/></p><p>According to the <i>Manager Magazin</i> article<i>,</i><b>Volkswagen</b>&#39;s luxury brand Porsche, best known for its 911 sports car, is reportedly developing an electric version of the 911 that could use solid-state batteries, and is working with QuantumScape to supply them.</p><p>Although neither QuantumScape nor Porsche have confirmed anything yet, investors were perhaps betting on this rumor proving  true, given the company&#39;s long-standing partnership with Volkswagen.</p><p>In 2021, QuantumScape received an additional $100 million worth of funding from Volkswagen after its battery cells met the automaker&#39;s technical milestone requirements in lab tests. The two companies have also signed an agreement to jointly develop a solid-state battery pilot-line facility.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"QS":"Quantumscape Corp."},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1149825957","content_text":"QuantumScape stock climbed 2% in premarket trading as QuantumScape's relation with Volkswagen could deepen further.According to the Manager Magazin article,Volkswagen's luxury brand Porsche, best known for its 911 sports car, is reportedly developing an electric version of the 911 that could use solid-state batteries, and is working with QuantumScape to supply them.Although neither QuantumScape nor Porsche have confirmed anything yet, investors were perhaps betting on this rumor proving  true, given the company's long-standing partnership with Volkswagen.In 2021, QuantumScape received an additional $100 million worth of funding from Volkswagen after its battery cells met the automaker's technical milestone requirements in lab tests. The two companies have also signed an agreement to jointly develop a solid-state battery pilot-line facility.","news_type":1},"isVote":1,"tweetType":1,"viewCount":241,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9030569249,"gmtCreate":1645756364592,"gmtModify":1676534061456,"author":{"id":"3556663321293713","authorId":"3556663321293713","name":"kkoh","avatar":"https://static.itradeup.com/news/043182d0397ab25b04de66a4ae86820d","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3556663321293713","authorIdStr":"3556663321293713"},"themes":[],"title":"buy nvidia","htmlText":"Nvidia earning exceed expectation. Buy nvidia on weakness.","listText":"Nvidia earning exceed expectation. Buy nvidia on weakness.","text":"Nvidia earning exceed expectation. Buy nvidia on weakness.","images":[],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9030569249","isVote":1,"tweetType":1,"viewCount":108,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9096771977,"gmtCreate":1644473142430,"gmtModify":1676533931327,"author":{"id":"3556663321293713","authorId":"3556663321293713","name":"kkoh","avatar":"https://static.itradeup.com/news/043182d0397ab25b04de66a4ae86820d","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3556663321293713","authorIdStr":"3556663321293713"},"themes":[],"title":"cpi data","htmlText":"If cpi data become worst stock market will sell off. Cpi data expected to increase 0.5% and and will above 17%.","listText":"If cpi data become worst stock market will sell off. Cpi data expected to increase 0.5% and and will above 17%.","text":"If cpi data become worst stock market will sell off. Cpi data expected to increase 0.5% and and will above 17%.","images":[],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9096771977","isVote":1,"tweetType":1,"viewCount":416,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}